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Iron deﬁciencyIron is essential for several vital biological processes. Its deﬁciency or overload drives to the development of sev-
eral pathologies. Tomaintain iron homeostasis, the organism controls the dietary iron absorption by enterocytes,
its recycling by macrophages and storage in hepatocytes. These processes are mainly controlled by hepcidin, a
liver-derived hormone which synthesis is regulated by iron levels, inﬂammation, infection, anemia and erythro-
poiesis. Besides the systemic regulation of iron metabolism mediated by hepcidin, cellular regulatory processes
also occur. Cells are able to regulate themselves the expression of the ironmetabolism-related genes through dif-
ferent post-transcriptional mechanisms, such as the alternative splicing, microRNAs, the IRP/IRE system and the
proteolytic cleavage. Whenever those mechanisms are disturbed, due to genetic or environmental factors, iron
homeostasis is disrupted and iron related pathologies may arise.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
The central role of iron in cells and organisms is widely known, as
many branches of essential metabolisms, encompassing a full range of
cellular processes, energy production, biosynthesis, replication and
locomotion, require iron in order to occur.
Despite being so important, it has toxic properties when presented
on its free form. Its regular ability tomediate electron transfer, changing
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austino).reactive oxygen species responsible for cellular and tissue damage. To
avoid those negative effects, iron is usually found coupledwith proteins.
In serum, it is mainly associated with transferrin, while within the cells
it is driven by chaperones or stored within ferritin.
In humans, erythropoiesis is the biological process with the highest
demand for iron atoms because of its requirement to heme synthesis
and subsequent incorporation into hemoglobin molecules. Circulating
erythrocytes consist mainly of hemoglobin containing four heme
groups that temporarily binds to oxygen molecules in the lungs and re-
lease them throughout the body. When senescent, erythrocytes are
phagocytized by macrophages and iron becomes available to be
reutilized. Consequently, an organism needs to absorb from diet only
the amount of iron strictly necessary to overcome the nonspeciﬁc
body iron losses. The control of dietary iron absorption by enterocytes
and its release from macrophages and from storing hepatocytes are
the main examples of mechanisms through which iron homeostasis is
maintained. Commonly, these processes are regulated by hepcidin, a
liver-derived hormone (Fig. 1). Hepcidin gene (HAMP) transcription is
up-regulated by high iron levels, infection and inﬂammation,while ane-
mia and erythropoiesis inhibit its expression. Hepcidin acts by binding
to the cell surface ferroportin-1 (Fpn1), the only known iron exporter,
inducing its internalization and degradation. As a consequence, iron re-
lease from enterocytes, macrophages and hepatocytes is prevented.
Besides the systemic regulation of iron homeostasis provided by
hepcidin, cells enclose both general and speciﬁcmechanisms to regulate
themselves the expression levels of iron metabolism-related genes. For
instance, the iron regulatory protein (IRP)/iron responsive element
(IRE) system controls bothmRNA stability and translation of transcripts
coding for proteins involved in iron uptake, export, transport and
Fig. 1. Systemic iron metabolism regulation. Themaintenance of iron homeostasis is a complex process that encompasses the regulation of (A) dietary iron by the duodenum enterocyte,
(B) usage by erythroblasts, (C) storage by hepatocytes and (D) recycling by splenic macrophages. After being reduced by ascorbic acid and Dcytb at the apical membrane of enterocytes,
dietary iron is absorbed by Dmt1 and driven to the basolateral membrane of these cells where it is exported by Fpn1 to circulation in association with transferrin (holo-Tf). Erythrocytes,
which are the cells that require themajor amounts iron, capture holo-Tf through themembrane-associated TfR1. After being endocytosed, iron is usedby themitochondria in the synthesis
of heme, which will be incorporated in the hemoglobin, functioning as a transporter of oxygen. Whenever the organism absorbs more iron than the required, it is stored within ferritin,
mostly at the hepatocytes. The most common source of iron are the macrophages, as they phagocyte the senescent erythrocytes, releasing iron from heme through the HO1, rendering it
available to be re-utilized by the cells. In the control of all of these processes we ﬁnd hepcidin, a circulatory protein synthesized in the liver accordingly to iron levels. Hepcidin acts by
binding to membrane-associated Fpn1, inducing its internalization and degradation and, consequently, preventing dietary iron absorption and release from storing hepatocytes and
recycling macrophages.
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environmental factors, iron overload or iron deﬁciency pathologies
may arise. This manuscript will provide a general view of the iron me-
tabolism regulatory mechanisms required to maintain homeostasis
and the causes and consequences of their deregulation.
2. Inorganic and organic iron
2.1. The origin of life
The ability to complexwith organic ligands is one of the reasonswhy
iron is a co-factor of several enzymes. In nature, it can be found in eight
oxidation states, ranging from−2 to+6 [1]. This redox propertymakes
iron useful for electron transfer reactions. Recently, it has been hypoth-
esized that, iron could have a crucial role on the origin of life. It is sup-
ported that it was an essential element for the development of the
primordialmembrane bioenergetics [2]. The process of serpentinization
at alkaline thermal vents generates natural proton gradients similar to
the ones used bymodern cells [3]. Brieﬂy, at high pressures and temper-
atures, iron-containing minerals, such as olivine, react with water to
form serpentine and high concentrations of magnetite and H2. The
thin mineral walls would form osmotic barriers separating the warmH2-rich alkaline ﬂuids from the cold, Fe2+-rich oxidized ocean. There,
it would have been gathered the conditions for the formation of primor-
dial natural proton gradients and, consequently, of the energy required
for the reduction of CO2, synthesis of complex organic compounds and
the development of the ﬁrst proto-cells.
2.2. Iron and evolution
Iron is an element required by almost all species within the six king-
doms of life. Before oxygenic photosynthesis, where O2 and H2O started
to cycle between photosynthesis and respiration, redox cycles took ad-
vantage of other elements in order to maintain microbial metabolism
[4]. Some bacteria and archea retain the ability to extract energy from
sources that are inaccessible to other organisms. For example, instead
of acquiring electrons fromwater, somephotosynthetic bacteria oxidize
Fe2+ to promote CO2ﬁxation (anoxygenic photosynthesis)while others
transfer electron from organic carbon to Fe3+ (heterotrophic respira-
tion) or obtain energy by oxidizing Fe2+ and reducing O2 or NO3
(lithotrophic respiration) [5].
Throughout evolution, and due to the increase of oxygen tension,
redox properties of ironmade it extremely useful, so that its usage in eu-
karyotes is focused on oxygenmetabolism, both as an oxygen carrier or
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proteins: iron–sulfur cluster-containing proteins (ISCs), heme-
containing proteins and iron-containing enzymes. ISCs catalyze chemi-
cal reactions or are components of electron transport complexes [6].
Heme-containing proteins play functions related to oxygen transport
or metabolism [7]. Finally, iron-containing enzymes play roles in a
vast range of reactions [8].
While Fe2+ is soluble in anoxic conditions, it becomes insoluble in
the presence of oxygen, being rapidly oxidized to Fe3+, a form that
can be solubilized by acidiﬁcation [9]. There are two mechanisms that
allow the organisms to acquire iron. One involves the acidiﬁcation of
the environment in order to solubilize Fe3+ and to promote its reduc-
tion to Fe2+ which will be transported across the plasma membrane.
The second approach is the synthesis and secretion of siderophores
(small organic molecules with afﬁnity for Fe3+) [10].
3. Iron metabolism in humans
The most common forms in the human body are ferrous (Fe2+) and
ferric (Fe3+) iron. The one-electron transfer between these oxidation
states is easily achieved in a way that regular reducing agents perform
the reduction of aqueous Fe3+ to Fe2+, while dioxygen (O2) promotes
the reverse reaction [9]. Under physiological O2 concentrations the
most stable form of iron is Fe3+. The reduction of O2 by Fe2+ results
in the formation of superoxide radicals [11]. The hydroxyl radical, one
of the most potent oxidants found in the organism, is responsible for
the attack to proteins, nucleic acids and carbohydrates, for triggering
the propagation of lipid peroxidation and, ultimately, cell apoptosis
[12]. Therefore, the organism has developed mechanisms to prevent
the toxicity of free iron. These mechanisms comprise the dietary iron
absorption by the duodenum, transport in the circulation, cellular up-
take and consumption, recycling by macrophages and storage in the
liver [13–16] (Fig. 1).
3.1. Absorption
Dietary iron is classiﬁed as heme or non-heme iron [17]. Heme iron
is highly abundant inmeat, as a component of the hemoproteins, hemo-
globin andmyoglobin. The lowpHof the stomach coupled to proteolytic
enzymes is responsible for heme release fromhemoproteins. Themech-
anism responsible for heme uptake is not yet well understood, however
it is known to occur by receptor-mediated endocytosis (Fig. 1A). The
heme-carrier protein 1 (HCP1), together with the proton coupled folate
transporter (PCFT), has been identiﬁed as the most probable receptor
involved in this process. However, it has low-afﬁnity to heme and is
more involved in folate absorption [18]. Dietary ferritin is also absorbed
by the enterocytes through an adaptor-related 2 protein complex
(AP2)-dependent endocytosis mechanism [19]. Once in the enterocyte,
heme is broken by heme oxygenase 1 (HO1) and iron is released in its
ferric state.
Non-heme iron is mostly presented to the organism on its oxidized
form (Fe3+). In order to be absorbed by the enterocyte, it is reduced
to Fe2+ by the low pH of the stomach together with ascorbic acid [17].
Differentiated enterocytes express on their surface the proteins re-
quired for dietary iron absorption. At the apical membrane, facing the
gut lumen, there are expressed proteins that facilitate iron reduction,
such as duodenal cytochrome b (DcytB) and, most probably, six trans-
membrane epithelial antigen of the prostate 2 (Steap2) [20,21], as
well as, the proton-coupled divalent metal transporter 1 (Dmt1), an
iron importer (Fig. 1A). Dmt1 is responsible for the absorption of the
ionic forms of iron, cobalt, zinc, cadmium and others. It is a transmem-
brane protein that takes advantage of the proton gradient existing be-
tween the gut lumen and the enterocyte cytoplasm, to perform the
symport of Fe2+ coupled with H+ [22].
In the cytoplasm iron is driven to the basolateral membrane of the
enterocyte, or stored in ferritin. Here, the ‘mucosal block’ mediated byferritin plays a crucial role on the effective absorption of iron. For in-
stance, it was shown that, in mice, when ferritin levels are upregulated
by the absence of the IRE/IRP system, iron is mostly stored at the
enterocyte instead of being delivered to the circulation, independently
of the iron status of the organism [23].
The export of iron from the enterocyte to the circulation is a crucial
step for the entrance of iron in the body. The enterocytes express on
their basolateral membrane the protein Fpn1, the only knownmamma-
lian iron exporter [24]. Fpn1 transports Fe2+ to the extracellular side of
the basolateral membrane, where it is oxidized by the ferroxidases,
hephaestin (Heph) and ceruloplasmin (Cp) in order to be associated
with the circulatory transferrin (Tf) [25,26] (Fig. 1A).
3.2. Transport and cellular uptake
Following absorption by the enterocyte, iron must be delivered to
cells for either general or speciﬁc functions (Fig. 1B). The stability of
transferrin-bound iron (TBI) is dependent on several factors, such as
the oxidation state of iron, the protein conformation and the environ-
mental pH. Tf is found in the plasma in three states: apo-transferrin
(apo-Tf), when no iron is bound; monoferric transferrin (bounded to a
single iron atom); and diferric transferrin, also known as holo-
transferrin (holo-Tf; bounded to two iron atoms) [27]. The concomitant
existence of these three states of Tf in a healthy individual allows the re-
sponse to acute increases of iron absorption, preventing the toxic effects
of excess of iron in the organism.
The cellular uptake of TBI is mainly mediated by the transferrin re-
ceptor 1 (TfR1), located at the cell membrane [28]. Upon cell surface
binding, the TBI–TfR1 complex undergoes a clathrin-dependent endo-
cytosis. The endosome pH decreases by the entry of H+ mediated by
an ATP-dependent proton pump, and Fe3+ is released, while apo-Tf re-
mains bound to TfR1. In the endosome, free iron is reduced by Steap 3
and transported to the cytoplasm by Dmt1 [22,29]. Meanwhile, the
Tf–TfR1 complex is driven to the cell surface where apo-Tf is released
to the plasma (Fig. 1B).
Non-transferrin bound iron (NTBI) species are also frequently found
in the plasma [30]. It has been suggested that the main form of NTBI is
Fe3+ bound to citrate. However, other iron transporters, such as acetate,
have been detected [31]. The origin and themechanisms involved in the
cellular uptake of plasma NTBI remain unclear. It is known that it has a
high-afﬁnity to hepatocytes and its uptake seems to be mediated by an
endocytosis-independent mechanism. The most probable NTBI trans-
porter that was so far identiﬁed is the zinc transporter Zrt–Irt-like
protein 14 (Zip 14) [32].
3.3. Consumption and storage
The organism has a high requirement for iron, being its majority
used by the erythroblasts for hemoglobin synthesis. About 70% of the
body iron pool is found as heme iron in erythrocytes [33]. Mitochondri-
on is the major human organelle responsible for maintaining the cellu-
lar iron homeostasis. After being released in the endosomes, iron is
driven to this organelle. Iron may be delivered to mitochondria both
by a cytosolic iron chaperon, the poly (rC) binding protein 1 (PCBP1)
[34], or directly from the endosome through a ‘kiss-and-run’ mecha-
nism. The latter was observed in the developing erythrocytes, which
have higher demands of iron for hemoglobin synthesis [35]. The trans-
port through the inner membrane is mediated by mitoferrins 1 and 2
[36]. Once in the mitochondria, iron is used in the biosynthesis of
heme and of ISCs, which are incorporated into several proteins involved
in electron transfer.
Iron storage prevents the presence of free iron whenever body iron
levels increase. It also ensures its immediate availability during iron de-
ﬁciency. The major protein responsible for iron storage is ferritin (Ft)
[37] (Fig. 1C). It exists as a 24-subunit multimer of heavy (Ft-H) and
light (Ft-L) polypeptide chains. When synthesized, these chains self-
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to 4500 iron atoms on its core. Cytosolic Fe2+ is driven to Ft by the PCBP
chaperones, being oxidized by the Ft-H subunits, while Ft-L subunit pro-
motes its uptake into the core [34]. Ft is localized in cell cytosol, nucleus
and mitochondria, but is also present in the serum (sFt). Mitochondria
express their own Ft-H-like chains, and it seems that mitochondrial Ft
(mFt) is able to store iron even more efﬁciently than the cytosolic one
[38]. The mechanisms used for iron release from Ft are thought to be
driven both by lysosome- and proteasome-mediated degradation
mechanisms [39,40]. It has been shown that the nuclear receptor coac-
tivator 4 (NCOA4) acts as a cargo receptor that binds and delivers ferri-
tin to ferritinophagy in lysosomes, thus regulating iron bioavailability
[41]. In agreement, NCOA4 expression is up-regulated during erythro-
poiesis, a process with high demands for iron [42]. Also, the importance
of NCOA4 in iron metabolism has been highlighted in Ncoa4−/−mice,
which developed a severe iron overload in splenicmacrophages, impor-
tant effectors of iron recycling from senescent erythrocytes [43].3.4. Recycling
One of the main functions of splenic and hepatic macrophages is to
scavenge the senescent erythrocytes in order to release iron from the
hemoglobin, rendering it available for another hemoglobin cycle [44]
(Fig. 1D). Recyclingmacrophages contribute to themajor pool of plasma
iron, exceeding the contribution of dietary iron absorption. There are
several alterations that are recognized by macrophages as erythrocyte
markers of aging [45–48]. These include modiﬁcations on the erythro-
cyte solute carrier family 4 (anion exchanger) member 1 (SLC4A1),
the presence of membrane phosphatidylserine, and the decrease of
membrane ﬂexibility, sialic acid and in the cluster of differentiation 47
(CD47) antigen. A combination of these modiﬁcations trigger erythro-
cyte phagocytosis by the macrophage.
Once in the phagolysosome, the erythrocyte is subjected to reactive
oxygen species (ROS) and hydrolytic enzymes that promote the release
of heme to the vacuolar ﬂuid. Then, HO1 together with O2 cleaves heme
to iron, carbonmonoxide and biliverdin [49]. Macrophages also capture
the hemoglobin released to the serum by ruptured erythrocytes. Plasma
hemoglobin complexes with haptoglobin, which is recognized by the
macrophage cell surface receptor CD163 [50] (Fig. 1D).
The transport of iron within the macrophage involves (i) the
movement of iron across the phagosome membrane by the trans-
porters Dmt1 and the natural resistance-associated macrophage
protein (Nramp1) [51]; (ii) the transport through the cytoplasm
mediated by the PCBP chaperones [34]; and (iii) the delivery of
Fe2+ to the Fpn1 for cellular export, followed by reduction by the
glycosylphosphatidylinositol-linked (Gpi)-Cp and consequent
binding to serum Tf [52].4. Iron metabolism regulation
The human organism has several mechanisms through which iron
levels are kept in homeostasis. Controlled iron absorption, recycling
and storage represent part of these mechanisms. Since there are no ac-
tive ways of excreting iron, the human body needs to absorb approxi-
mately 1 mg of dietary iron every day. This process overcomes the
non-speciﬁc iron losses through bleeding, sweat and sloughing of epi-
thelial cells. However, changes in the absorption, storage and cellular
iron release may occur. Whenever more iron is required, the organism
increases its duodenal absorption and release from macrophages and
from storing cells. On the other hand, when facing conditions of iron
overload the absorption is inhibited and storage increased, in order to
prevent the toxic effects of free iron excess [53,54]. All the steps re-
quired for keeping iron homeostasis are strictly regulated at both sys-
temic and cellular levels.4.1. Systemic regulation
The major known regulator of iron homeostasis is hepcidin, a 25
amino-acid (aa) peptide hormone mainly expressed by the liver [55].
Its expression is regulated by several physiological conditions, such as
systemic iron levels, hypoxia, anemia, erythropoiesis, infection and in-
ﬂammation [56–58] (Figs. 1C and 2).
Hepcidin is expressed from theHAMP gene located at the long armof
chromosome 19 (19q13.1). It is ﬁrstly synthesized as a biologically inac-
tive 84 aa pre-proprotein, comprised of a signal peptide, a pro-region
and the fully-active 25 aa sequence [59]. Its maturation occurs within
the cell and it is performed by proteolytic cleavage mediated by the
prohormone convertase furin [60]. Hepcidin acts by triggering Fpn1 in-
ternalization and, consequent degradation [61] (Fig. 1). It was proposed
that hepcidin binding to Fpn1 induces a rapid ubiquitination of the lat-
ter, responsible for its internalization [62].
Therefore hepcidin regulates systemic iron metabolism by reducing
Fpn1 levels and consequently, dietary iron uptake and release from
macrophages, hepatocytes and other cell types. The eliminationmecha-
nism of serum hepcidin has been poorly studied. Hepcidin is found in
urine as a 20–25 aa peptide. It is still controversial, whether hepcidin
degradation is a consequence or the cause of kidney ﬁltration [63,64].
Hepcidin ismainly expressed in the liver, although its expression has
been also detected inmacrophages, pancreatic beta cells, kidney, adipo-
cytes and lung [63,65–68].While iron overload, infection and inﬂamma-
tion up-regulate HAMP expression [56,69,70], iron deﬁciency, hypoxia,
anemia and erythropoiesis act on the opposite way [57,58] (Fig. 2).
4.1.1. Iron levels
The regulation of HAMP expression by iron levels is a process
through which the human body avoids both the toxic outcomes of
iron overload and the negative physiological consequences of its deﬁ-
ciency. Several proteins located at the surface of hepatocytes are consid-
ered to be ‘iron sensors’. These are hemojuvelin (Hjv), HFE, TfR1, and
TfR2 (Fig. 2A).
One of the pathways involved inHAMP expression regulation by iron
is the Hjv-bone morphogenetic protein (BMP) axis [71]. Hjv is a
Gpi-linkedmembrane protein that is considered to be themajor regula-
tor of HAMP expression in the liver. Hjv acts at the cell surface as a
co-receptor of BMPs, a subfamily of cytokines belonging to the
transforming growth factor β superfamily [72]. Despite BMPs playing
an important role in human development, it is long known their role
in iron homeostasis regulation. The Hjv–BMP signaling pathway is trig-
gered upon BMPs binding to Hjv and BMP receptor (BMPR) complexes.
The activated receptors induce the phosphorylation of cytosolic SMADs
1, 5 and 8 [71,73,74]. The phosphorylated SMADs form complexes with
SMAD4, which are translocated to the nucleus where they bind to the
BMP responsive elements (BMPREs) present at HAMP promoter, induc-
ing its transcription [75,76]. The BMPs that have been identiﬁed as acti-
vators of HAMP expression are BMPs 2, 4, 5, 6, 7, and 9 [71]. However,
only the knockout in mice of BMP6 drives to an iron loading phenotype
similar to the ones observed for the knockouts ofHJV andHAMP, reveal-
ing its high importance in iron metabolism regulation [77,78]. The
mechanisms regulating BMP expression seems to involve iron but are
far to be known. However, it was shown that BMP6 mRNA levels corre-
late positively with both body iron and hepcidin levels [79]. The expres-
sion of BMP6 occurs majorly in the liver. However, while hepcidin is
synthesized by the hepatocytes, BMP6 expression in response to iron
occurs preferentially at non-parenchymal liver cells, such as sinusoidal
endothelial cells, hepatic stellate cells and Kupffer cells [80]. So, when-
ever iron levels increase in the body, BMP6 is produced by these cells,
secreted to the interstitial environment, where it binds to the Hjv in he-
patocyte, triggering hepcidin expression.
Although the Hjv–hepcidin axis represents the most important
mechanism for the up-regulation of HAMP expression during iron over-
load, there are other fewmechanisms that can restrain its way of action
Fig. 2.Mechanisms of HAMP gene expression regulation in the hepatocyte. (A) The increase of iron levels and (B) inﬂammation and infection up-regulate the expression of HAMP gene,
while (C) hypoxia and (D) anemia and erythropoiesis repress its expression. The mechanisms involved in the up-regulation comprise the recognition of circulatory proteins, as holo-Tf,
BMPs and ILs, bymembrane-associated proteins. This recognition trigger ERK/MPK, SMAD and JAK-STAT signaling pathways that culminate in the activation ofHAMP gene expression. On
the other hand, both soluble and membrane proteins, such as sHJV and MT2, are known to repress the SMAD signaling pathway by arresting BMPs or degrading mHJV, respectively. In
hypoxic conditions, the HIF-1 protein complex is stabilized, being able to bind toHAMP promoter and repressing hepcidin transcription. Also, during anemia and expanded erythropoiesis
circulatory proteins are produced (GDF15, TWSG1 and erythroferrone), which will act through yet unknown membrane receptors to repress HAMP expression, possibly by inhibiting
SMAD and JAK-STAT signaling pathways.
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[81,82]. Its cleavage product is secreted from the cells as a soluble
form (sHjv). The subcellular location where furin-mediated cleavage
takes place is controversial since, in the literature, two positions were
reported, in the endoplasmic reticulum (ER) and in the trans-golgi net-
work [81,83]. When released to the extracellular environment, sHjv is
thought to act as an antagonist of HAMP expression by high-jacking
the BMPs, preventing them to bind to the membrane Hjv and to trigger
the signaling pathway [71,83].
Besides furin-mediated cleavage, Hjv is also a target to cleavage by
matriptase-2 (MT2), a protein predominantly expressed in the liver
and an hepcidin expression suppressor [84]. In vitro studies suggest
thatMT2 binds to themembraneHjv cleaving it in a ladder of fragments
that are subsequently released to the medium [85].
The pathway through which Hjv triggers the expression of HAMP is
well characterized, however there are some aspects regarding Hjv
membrane stabilization that are not yet disclosed. For instance, in the
cell surface Hjv interacts with neogenin (Neo) [86]. The role of this pro-
tein seems to be bidirectional. Neo is either required for HJV-mediated
hepcidin expression, as well as for sHjv production and Hjv cleavage
by MT2, inhibiting hepcidin production [87,88].
Another pathway responsible for the regulation of hepcidin expres-
sion dependent on iron levels involves themembrane proteins HFE and
TFR2 (Fig. 2A). Under iron homeostatic conditions, HFE is partially local-
ized at the hepatocyte cell surface bound to TfR1 [89].Whenever plasma
iron levels increase, the iron loaded transferrin (Fe2-Tf) gains high afﬁn-
ity for the same receptor. Since the TfR1 binding sites for HFE and Fe2-Tf
overlap, and as the TfR1 afﬁnity for Fe2-Tf is higher than for HFE, itdissociates from this receptor and becomes available to associate with
TfR2 [69,90]. The formed Fe2-Tf–TfR2–HFE complex triggers the ERK1/2
signaling pathway and ultimately HAMP expression [91]. The cytosolic
proteins involved in this pathwayhave not been determined.Moreover,
it has been reported that, in mice, the knockouts of HFE and TFR2, alone
or together, have slightly different outcomes regarding HAMP expres-
sion [92]. Therefore, it is accepted that both HFE and TfR2 may trigger
other signaling pathways independent of each other. Whether HFE
and TfR2 interact and form a complex containing Hjv at the lipid rafts
within cell membrane also remains controversial [93,94]. Nevertheless,
it was recently shown that HFE interacts with the BMP receptor ALK3,
promoting its stabilization at cell surface by inhibiting its ubiquitination
and proteasomal degradation, though regulating the expression of
hepcidin [95].
4.1.2. Infection and inﬂammation
Similar to other organisms, pathogens require iron for survival and
proliferation. Whenever the human body is infected, the pathogen
takes advantage of the host's iron pool, for its own needs. The
hypoferremia commonly associatedwith the infection is one of the sev-
eral innate and adaptive responses of the immune system [70]. By low-
ering the iron levels, the organism tries to arrest the proliferation of
iron-dependent pathogens avoiding a fast septicemia outcome and
allowing an effective elimination of the infection.
The induction of the hypoferremia during inﬂammation/infection is
mediated by hepcidin [96]. For instance, the injection of hepcidin in
mice induces a rapid decrease in serum iron levels [97]. As circulatory
hepcidin levels increase, Fpn is internalized and degraded prompting
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arrest the body iron pool in macrophages and storing cells. During
infection, pathogens are recognized as foreign elements by several
cell types, such asmacrophages. This recognition triggers the expression
and secretion of the pro-inﬂammatory cytokines interleukin (IL)-6, -22
and type-1 interferon (INF) [70,96,98,99] (Fig. 2B). This cytokines are
recognized by surface Toll-like receptors expressed by hepatocytes
and leukocytes, triggering the Jak-signal transducer and activating the
transcription 3 (Stat3) pathway. The translocation of factor Stat3 to
the nucleus and its binding to the Stat3 binding sites in the HAMP pro-
moter trigger the expression of this gene [100]. Therefore, extracellular
pathogens are deprived of iron.
4.1.3. Hypoxia
Erythropoiesis is the process through which red blood cells are pro-
duced and, consequently, the oxygen transporter hemoglobin. During
hypoxia, erythropoiesis increases in order to overcome the lowbody ox-
ygen levels.
The hypoxia inducing factor (HIF) system is recognized as being the
main modulator of both iron metabolism and erythropoiesis during
hypoxia [101] (Fig. 2C). HIFs are transcription factors that bind to the
hypoxia-response elements (HREs), controlling gene transcription
[102]. HIF protein levels are regulated by oxygen. Under normoxia, all
HIFα-subunits are targeted for proteasome degradation [103]. Under
hypoxia, the stabilized HIFs regulate the expression of TF, TFR1, and
CP, aswell as ofHMOX, SLC11A2, CYBRD1 and EPO (the genes responsible
for the expression of HO1, Dmt1, DcytB and erythropoietin, respective-
ly) [104–107]. While HIF-2 has been shown to increase the expression
of SLC11A2 and CYBRD1, though enhancing intestinal iron uptake,
HIF-1 has been suggested to play a role in the inhibition of HAMP ex-
pression in the liver, through a HRE-mediated mechanism [57].
However, it remains controversial the way how HIF-1 acts on HAMP
expression. Despite the promoter of hepcidin gene presenting consen-
sus sequences for hypoxia responsive elements, both the overexpres-
sion and knockdown of HIF-1α do not affect the expression of
hepcidin [108,109]. On the other hand, some data supports an indirect
regulation of hepcidin expression by HIF-1. For instance, HIF-1 up-
regulates the expression of furin and consequently an indirect down-
regulation of HAMP expression [81]. Also, it has been recently shown
that the platelet derived growth factor BB (PDGF-BB), which expression
is upregulated byHIF-1 during hypoxia, is responsible for the repression
of hepcidin expression mediated by the downregulation of both CREB
and CREB-H transcription factors [110,111].
4.1.4. Anemia and erythropoiesis
Ineffective erythropoiesis is responsible for a hypoxic condition ob-
served during anemia. Erythropoietin (Epo) is a glycoprotein hormone
mainly synthesized in the adult kidney [112]. It prevents the apoptosis
of the colony-forming unit-erythroid cells and erythroblasts that have
not begun the synthesis of hemoglobin [101]. Hypoxia is the primary
known physiological stimulus that controls Epo production. According
to hypoxia severity, Epo serum levels may raise up to 100-fold of the
levels found during normoxia. It was shown that, in mice, HIF-2 en-
hances Epo expression in the liver during hypoxic conditions [113].
Since hypoxia is the main regulator of Epo and consequently erythro-
poiesis, it was believed for a long time that the down-regulation of
hepcidin expression observed during anemia was a consequence from
hypoxia rather than from erythropoiesis itself. However, it was reported
that the administration of erythropoietin to healthy individuals lowered
the levels of circulatory hepcidin, while no immediate changes of iron
levels were detected [114]. This outcome led to the search of a
hepcidin-suppression factor that could be expressed by the erythroid
precursors in response to Epo. Two BMP familymembers, the growth dif-
ferentiation factor 15 (GDF-15) and the twisted gastrulation 1 (TWSG-1)
are up-regulated in pathologies that present an expanded but ineffective
erythropoiesis, as β-thalassemia and congenital dyserythropoieticanemias [115–117] (Fig. 2D). GDF-15 was shown to regulate hepcidin
expression in hepatoma cells but its speciﬁc role in the regulation of
iron homeostasis or in the development of pathological iron-related con-
ditions remains elusive. Recently, it was discovered a new hormone,
erythroferrone, produced by the erythroblasts in response to erythropoi-
etin during the erythropoiesis process, which is responsible for the re-
pression of hepcidin expression (Fig. 2D). However, its action is
independent on the BMP–SMAD pathway, as well as, on TfR2 [118]. The
transcription factor Atoh8 is a possible mediator of this process as it in-
duces hepcidin expression in HEK293 cells, as well as, its expression is
downregulated in conditions associated with high erythropoietic
activity [119].
4.2. Cellular regulation
While hepcidin plays a crucial role in the systemic regulation of iron
metabolism, cells present other mechanisms that speciﬁcally regulate
the expression of iron metabolism-related genes. These include the
modulation of general cellular mechanisms that give rise to alternative
transcript variants (such as alternative transcription initiation,
polyadenylation and splicing) or of more speciﬁc systems that control
the stability of the mRNAs and proteins.
4.2.1. Transcriptional initiation
Gene transcription initiation is a complexmechanism throughwhich
RNApolymerases recognize theDNA sites fromwhere the RNA synthesis
should be started. So far,DMT1, SLC40A1 (gene that expresses Fpn1) and
TFR2 are the only iron metabolism-related genes described as having
more than one transcription initiation site associated with alternative
promoters [120,121].
DMT1 transcription is regulated by two alternative promoters that
give rise to two 5′ DMT1 protein variants which differ in the
N-terminal sequence (the variant originated by the transcript with the
upstream 5′ exon has an additional 29 N-terminal residues). The
expression of this upstream 5′ exon variant seems to occur preferential-
ly in the kidney and duodenum [122]. The transcription of SLC40A1 orig-
inates two mRNAs, FPN1A and FPN1B, with different 5′-regions but
coding for the same protein [120]. However, only the FPN1AmRNA con-
tains an IRE motif, being regulated by iron levels. FPN1B is only
expressed in the duodenum and in the erythroid precursors. On the
other hand, the transcripts that are produced by the alternative TFR2
transcription sites, give rise to two slightly different proteins [121].
The TFR2α transcript originates the full-length membrane protein in-
volved in the regulation of hepcidin expression, while the TFR2β tran-
scription is initiated within the TFR2 DNA sequence corresponding to
the intron 3 of TFR2α. The protein originated by TFR2βmRNA is similar
to the full-length TFR2 however it lacks the intracellular and transmem-
brane domains. The knockout of the TFR2β in mice showed that it plays
a role in the transcriptional control of SLC40A1 in the spleen and, there-
fore, in the control of the iron efﬂux from this organ [123].
4.2.2. Post-transcriptional regulation
It is estimated that almost all human genes suffer post-
transcriptional regulation [124] throughmechanisms such as, the alter-
native polyadenylation, the alternative splicing, and also all the regula-
tory mechanisms that affect the RNA stability, translation and protein
processing. For instance, iron metabolism post-transcriptional regula-
tion is mediated by both speciﬁc systems that regulate mRNA stability
and its translation, such as the IRP/IRE system, aswell as by general pro-
cesses, such as the microRNAs and protein proteolytic cleavage.
4.2.2.1. Alternative polyadenylation. Poly(A) tails are found in the 3′-ter-
minal region of almost all eukaryotic fully-maturatedmRNAs [125]. The
size of a poly(A) tail inﬂuences mRNA stability, translation and trans-
port. Alternative polyadenylation occurs whenever the polyadenylation
factors fail to recognize the main poly(A) consensus sequence, binding
Table 1
Iron metabolism genes which expression is regulated by microRNAs.
Target MicroRNA Reference
HFE; HJV miR-122 [183]
TFR1 miR-320, miR-210 [184,185]
ISCU1/2 miR-210 [185]
Lactoferrin miR-214 [186]
Lactoferrin receptor miR-584 [187]
DMT1-non IRE miR-let-7 [188]




HIF-1α, HIF-2α mir-199a [150]
TFR2 miR-221 [151]
IRP1 miR-200a, miR-223 [152]
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sponsible for the existence of the 6.4, 4.0 and 3.7 kb mRNAs [126]. The
3.7 kb transcript is preferentially expressed in iron-depleted cells, possi-
bly as a response to the high needs of IRP-2 protein during iron deﬁcien-
cy, since this RNA ismore stable and efﬁciently translated. Also,HFE has,
at least, four active poly(A) signals [127,128]. The most upstream signal
is responsible for the generation of an mRNA that is resistant to the
nonsense-mediated mRNA decay (NMD) mechanism, possibly being
recognized more efﬁciently in cells that require increased amounts of
the HFE protein [128].
4.2.2.2. Alternative splicing. Splicing is probably the post-transcriptional
mechanism that brings more variability to gene expression [129]. It is
responsible for the production of different proteins from the same
gene. The HFE gene produces several alternative transcripts [127,130].
From those, the ones corresponding to the inclusion of the total or par-
tial HFE intron 4 give rise to a soluble form of the HFE protein (sHFE),
which regulates the expression of hephastin in the duodenum through
a clathrin-independent, dynamin-mediated and RhoA-regulated endo-
cytosis mechanism. So, sHFE acts, most likely, as a regulator of dietary
iron absorption in the duodenum [131]. On the other hand, SLC11A2 al-
ternative splicing gives rise mainly to two variants, the DMT1A and
DMT1B, which are the result of the alternative usage of the 3′-exons of
the gene. This way the DMT1A variant presents an IRE and produces a
protein that is preferentially expressed in the epithelium. On the other
hand, DMT1B does not have the IRE, thus it does not respond to iron,
and it is expressed mainly by blood cells [132]. Also, CP is a target for
post-transcriptional processing by alternative splicing giving rise to
twomain Cp isoforms, the sCp and theGpi-Cp. These are the result of al-
ternate usage of exons within the 3′ region of CP [133].
4.2.2.3. The IRP/IRE system. In general, mechanisms of post-
transcriptional regulation play an important role in the maintenance
of cellular iron metabolism. In fact, cells have developed a speciﬁc
mechanism to control the translation and the stability of iron
metabolism-related mRNAs. The IRP/IRE system was developed by the
cell to maintain the cellular iron content through the regulation of its
uptake, storage and export [134]. The IRP1 and IRP2 proteins are the
main regulators of cellular iron in humans [135,136]. They bind to the
IREs present at the 5′ and 3′-untranslated regions (UTRs) of mature
mRNAs that code for proteins responsible for iron uptake (Dmt1 and
TfR1), storage (Ft-H and Ft-L) and export (Fpn1) [134]. IREs are 28–30
nucleotide sequences with a highly conserved secondary structure.
During iron deﬁciency, IRP1 binds to IRE through a cavity on its struc-
ture, while under iron overload that same cavity is occupied by the
4Fe–4S cluster and unavailable to bind to the IRE [137,138]. The activity
of IRP2 is regulated by iron in a different way. An increase of cellular
iron promotes IRP2 ubiquitination and consequent proteosomal degra-
dation, therefore preventing its binding to the IRE [139]. This process is
mediated by E3 ubiquitin ligase complex containing the F box and
leucine-rich repeat protein 5 (FBXL5). FBXL5 stabilizes after the binding
of iron and oxygen to its hemerythrin domain, promoting IRP2
ubiquitination [140]. Also, the knockout of FBXL5 gene induces a mas-
sive iron overload that is fatal to the embryos. This phenotype is only
prevented by the concomitant knockout of the IRP2 gene [141].
When cells are deprived from iron, IRPs bind to the IREs located at
the 5′UTRs of FTH and FTL and SLC40A1, preventing ribosome assembly
and further translation [142,143]. On the other hand, they also bind to
the IREs located at the 3′UTR of TFR1 and SLC11A2 increasing their sta-
bility and consequently their translation [144,145]. This way, iron up-
take is up-regulated while iron storage and export are inhibited.
When iron levels increase, IRPs are not able to bind to the IREs, limiting
cellular iron acquisition.
4.2.2.4. MicroRNAs. The non-coding RNAs have assumed an extraordi-
nary importance in the last few years when it became clear that theyhave critical functions in physiological processes (such as cell differenti-
ation and development) but also in pathological processes. MicroRNAs
are non-coding RNAs with an average length of 22 nucleotides which
function is being antisense regulators of other RNAs [146]. Originally,
they are expressed within the nucleus as longer RNAs (pri-microRNAs)
with a stable hairpin structure and are subsequently processed by
Drosha into ~70 nucleotide microRNA precursors (pre-microRNAs)
that are translocated to the cytoplasm and processed by Dicer into
double-stranded ~22 nucleotidemicroRNAs. Then, one of themicroRNA
strands is assembled to the RNA-induced silencing complex (RISC),
followed by binding to the target mRNA and consequent translation in-
hibition and/or degradation [147].
In recent times, it has been clear that microRNAs are implicated in
iron metabolism regulation, as well as, in the development of
iron-related disorders. Most of microRNAs involved in those processes
were reviewed by Davis and Clarke [148] but, more recently, few others
were reported (Table 1). The latter group consists of microRNAs-130,
-199a, -221, -200a and -223. MicroRNA-130 was found upregulated in
the liver of iron-deﬁcient mice. It targets the BMPR Alk2 and, conse-
quently, represses hepcidin expression [149]. MicroRNA-199a targets
the 3′-UTRs of HIF-1α and HIF-2α. Under hypoxia, the microRNA-
199a expression is decreased, which consequently promotes increased
HIF levels. It was demonstrated a regulatory relationship between
microRNA-199a and HIF with implications in ovarian cancer metastasis
[150]. Moreover, microRNA-221was shown to regulate TFR2 expression
in an in vitromodel of Parkinson disease [151]. Finally, both microRNA-
200a and microRNA-223 expressions are inversely correlated with the
expression of IRP1 in mice with induced nonalcoholic fatty liver disease
[152].
Interestingly, iron has been shown to be a crucial element during the
biogenesis ofmicroRNAs. For instance, the activity of DGCR8 (a co-factor
for Drosha) is affected in vitro by the absence of heme-iron and,
consequently, it perturbs the processing of pri-microRNAs to
pre-microRNAs [153].Moreover, it was also found that the free cytosolic
iron prevents pre-microRNA processing to mature microRNA by
‘sequestering’ PCBP2, a co-factor for Dicer protein [154].
4.2.2.5. Proteolytic cleavage. The production of many secreted proteins is
dependent on the proteolysis of a precursor protein at speciﬁc internal
sites by a conserved family of proprotein convertases (PCs) [155]. The
shedding of TfR1 from cellular membrane is mediated by PC7. This is a
ubiquitously expressed convertase which is located within the trans-
golgi network and the cell surface [156]. The function of the formed sol-
uble TfR1 (sTfR1) remains unclear. However, its levels in plasma are
useful to differentiate between anemia of inﬂammation and iron deﬁ-
ciency anemia. PC7 mRNA and protein levels are regulated by iron sta-
tus [156]. As described before, membrane Hjv may also be cleaved
giving rise to sHjv, an antagonist of the membrane Hjv by sequestering
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expression [71,81–83]. The cleavage of Hjv is mediated by the PC-like
protein, furin.
Hepcidin is initially expressed as pre-proprotein [59]. This protein
precursor is presented as an 84 aa peptide that contains a N-terminal
24 aa sequence that targets the nascent protein for the ER. To bematured,
hepcidin undergoes two cleavages to removeﬁrstly the signal peptide se-
quence and then the pro-region. Since prohepcidin precursor has a signal
peptide for the ER it is believed that the ﬁrst cleavage occurs in this com-
partment through an enterokinase-like protein, forming the prohepcidin.
As prohepcidin keeps to be processed, itmay be translocated to the trans-
golgi network where it is cleaved on its pentarginyl motif by furin [60,
157]. This way it is formed the bioactive 25 aa hepcidin, that is secreted
to the circulation.
5. Iron metabolism disorders
Despite the existence of a highly organized and regulated network
that keeps the body iron homeostasis, several factors either at genetic,
physiological or environmental levels may drive to the development
of iron overload or deﬁciency conditions (Table 2). During iron overload
it is observed a deposition of this metal in the liver, heart, as well as in
other tissues [158]. When the iron overload is triggered by an increase
in dietary absorption, iron accumulates in parenchymal cells of the
liver, forming a gradient of deposition decreasing from the periportal
hepatocytes to the centrilobular hepatocytes. If the origin of iron over-
load is associated with an uncontrolled release from macrophages,
iron accumulates at the mesenchymal level [159]. Here, it is observed
a punctual deposition of iron in the hepatocytes that surround the
macrophages.
The iron overload disorders are classiﬁed as genetic or acquired.
Within the genetic disorders we can ﬁnd the four types of hemochro-
matosis, aceruloplasminemia, atransferrinemia and others [159].
The acquired iron loading diseases are not directly originated by mu-
tations in iron metabolism genes. They give rise to a secondary iron
overload.
The deﬁciency of iron in the organism results in the development of
several types of anemia. Iron deﬁciency may also be classiﬁed as ac-
quired or genetic. The most common examples of iron deﬁciency pa-
thologies are the iron deﬁciency anemia (IDA), anemia of chronic
diseases (ACD) and the iron-refractory iron-deﬁciency anemia (IRIDA)
[160–162].Table 2
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Microcyti5.1. Iron overload disorders
Hereditary hemochromatosis (HH) is the most frequent iron over-
load disease characterized by an excessive parenchymal iron deposition
in vital organs such as the liver, heart and pancreas. The several hered-
itary forms conduce to the same pathological mechanism of entry of
iron to the plasma in amounts higher than the required to sustain the
iron-depending processes, such as the erythropoiesis. The severity of
the different forms of HH is variable, however they present common
features. The uncontrolled plasma iron ingress results primarily in an in-
creased Tf saturation and then in parenquimal iron deposition at several
organs, what may drive to cirrhosis, hypogonadism, cardiomyopathy,
arthropathy, diabetes and hepatocellular carcinomas [163].
The molecular mechanism that is usually affected in HH is the iron
sensing-hepcidin axis. In this disease, hepcidin levels are abnormally
low despite the high iron status presented by the body [164–168].
According to the clinical outcomes of the disease and the genes affected,
HH is divided in four types: (i) HFE-related HH, (ii) juvenile hemochro-
matosis, (iii) TFR2-associated hemochromatosis and (iv) ferroportin
disease.
The HFE-related HH, also known as classic HH or HH-type I is the
mildest form of the disease, being characterized by a gradual deposition
of iron in organs along life with major clinical manifestations in males
with ages higher than 40–50 years old and post-menopausal women
[163]. It is characterized by elevated Tf saturation (TfSat) and sFt levels.
Clinically it is responsible for fatigue, dark skin and hepatomegaly
symptoms. It represents approximately 90% of the total cases of hemo-
chromatosis [169]. The most frequent mutation associated with HFE-
related HH is the p.C282Y [164]. It is most frequent in individuals of
north-European descent, with an allelic representation of
approximately 6%. It is estimated that 1:200 to 1:300 Caucasians are ho-
mozygous for this mutation [170]. The majority of the individuals with
hemochromatosis are actually homozygotes for p.C282Y. Biologically,
the cysteine–tyrosine substitution disrupts the formation of the disul-
ﬁde bond that physiologically occurs between C225 and C282 residues,
and that is essential for HFE association with beta2-microglobulin
(β2M) [171]. Therefore the p.C282Y mutated HFE protein is unable to
bind to β2M and to be transported to the cell surface where it would
interact with TfR1 and TfR2 in order to regulate hepcidin expression.
The retention of the C282Y mutated HFE in the ER is known to trigger
the unfolded protein response (UPR) [172]. It has been shown that the
efﬁciency of this process may modulate the clinical outcomes ofd biochemical features
high TfSat fatigue, tissue iron deposition, hepatomegaly.
high TfSat cardiomyopathies and reproductive defects.
high TfSat fatigue, tissue iron deposition.
in disease, form A — high sFt, normal or low TfSat, iron accumulation within splenic
ic macrophages.
in disease, form B — high sFt, high TfSat, tissue iron accumulation, preferentially
patocytes, cardiomyopathies, and reproductive defects.
normal TfSat, cataracts.
generation, ataxia, dementia, diabetes, parenchymal iron accumulation.
c and hypochromic anemia, tissue iron overload, increased sFt, low Tf.
c and hypochromic anemia, fatigue, immune dysfunction, neurocognitive
nt.
c and hypochromic anemia, fatigue, immune dysfunction, neurocognitive
nt.
c and hypochromic anemia, unresponsive to treatment with oral and intravenous iron
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calreticulin (a protein involved in UPR) present a lower phenotypic pre-
sentation of the disease [173].
Another HFE variant has also been associated with HFE-related HH,
the p.H63D [164]. This variant has a higher prevalence in the general
population than the p.C282Y (the average allelic frequency of H63D is
14%); however, only when presented in a compound heterozygous
state with p.C282Y is considered as a risk factor for the development
of HH [174].
The other forms of HHpresentworst clinical outcomes than the ones
driven by the HFE-related HH. The Juvenile hemochromatosis (JH), also
known as HH-type II is a rare disease of iron overloadmetabolism. It oc-
cursmainly due tomutations in theHJV andHAMP genes [165,166]. The
age of onset of the disease is at 15–20 years old and the clinical out-
comes of the disease are cardiomyopathies and reproductive defects.
It is characterized by a severe iron overload driven by the full saturation
of Tf, high sFt levels and iron deposition [163].
The HH-type III is similar to the HFE-related HH. However, it is origi-
nated bymutations in the TFR2 gene. It leads to increased TfSat and sFt at
the average age of 30–40 years old [163,168]. Finally, theHH-type IV, also
known as ferroportin disease, is an iron overload disease with a autoso-
mal dominant transmission, associated with mutations in the SLC40A1
gene. Two forms are considered. In form A (also known as classic) the
ferroportin loss of function mutants are unable to export iron from cells
leading to cellular (especially macrophage) iron accumulation with de-
creased availability of iron for serum transferrin, which is reﬂected in
low transferrin saturation [163]. On the other hand, in ferroportin disease
form B mutations are responsible for a gain of function with full iron ex-
port capacity but insensitivity to down-regulation by hepcidin, so iron is
constitutively absorbed at the enterocyte and released by cells, resulting
in increased TfSat and parenchymal iron overload [167].
In addition to the above described types of hereditary hemochroma-
tosis other iron overloaddisordersmay occur. One is caused bymutations
in FTLwhich may drive to increase of ferritin levels in young individuals
and consequently the development of the hyperferritinemia–cataract
syndrome [175]. Another rare iron metabolism-related disease is
aceruloplasminemia which arises as a consequence of mutations in the
CP gene. Due to the importance of the ceruloplasmin protein in the
brain, the main symptoms of aceruloplasminemia are brain iron deposi-
tion, retinal degeneration, ataxia and dementia [176]. On the other
hand, atransferrinemia is amicrocytic and hypochromic anemia associat-
edwith tissue iron overload, increased sFt and low levels of Tf due tomu-
tations in transferrin gene [177]. While the hyperferritinemia–cataract
syndrome has a dominant pattern of transmission, aceruloplasminemia
and atransferrinemia are recessive disorders.
5.2. Iron deﬁciency pathologies
Iron deﬁciency anemia (IDA) is the most common nutritional
deﬁciency worldwide. It occurs more frequently in determined groups
of individuals, such as the premenopausal woman, children, hospitalized
individuals that require frequent diagnostic blood sampling and blood
loosing patients [178]. Also, it may arise as a consequence of an
iron-poor diet. The most harmful outcome of IDA is a microcytic and
hypochromic anemia [160] that, in its worst degrees is manifested by
fatigue, impairment of thermoregulation, immune dysfunction and
neurocognitive damage that can lead to psychomotor and cognitive
abnormalities in children [179,180].
Anemia of chronic diseases (ACD) is a condition that arises from in-
dividual presenting a permanent state of inﬂammation as a conse-
quence of a chronic disease [161]. During inﬂammation, macrophages
produce high levels of IL-6, the pro-inﬂammatory cytokine that triggers
the expression of hepcidin and, consequently, lowers dietary iron ab-
sorption and stored iron release [70], leading to anemia development.
Despite the acquired conditions of iron deﬁciency, there are also
genetic determinants responsible for the etiology of anemia. Theiron-refractory iron-deﬁciency anemia (IRIDA) is one of these exam-
ples [181]. It is characterized by congenital microcytic and hypochromic
anemia, low mean corpuscular erythrocyte volume, low TfSat, unre-
sponsiveness to oral iron administration, abnormal iron utilization
after parenteral iron administration and a recessive pattern of transmis-
sion. IRIDA is detected in early life and is developed due to mutations in
the MT2 producing gene (TMPRSS6) [182]. The spectrum of TMPRSS6
mutations associatedwith IRIDA iswide. Sincematriptase-2 is a negative
regulator of hepcidin expression by the cleavage ofmembraneHjv, levels
of hepcidin in IRIDA patients are extremely high and consequently the
absorption of dietary iron by the duodenum is impaired [85].
6. Conclusions
In conclusion, iron is an essential element for a vast range of biolog-
ical processes, however, it does also have toxic properties when on its
free state. In this manuscript we have reviewed the molecular mecha-
nisms responsible for themaintenance of ironhomeostasis in the organ-
ism. We have also described the most common pathologies that may
arise from the dysregulation of those mechanisms. However, the ﬁeld
of iron metabolism regulation is far from being understood, therefore
more research is needed to deepen the knowledge in this ﬁeld. While
hepcidin has been assumed, for long years, as being the primordial reg-
ulator of iron homeostasis, we cannot neglect the vital importance of
other mechanisms involved in iron metabolism regulation. In future,
those mechanisms might be considered for the design of new effective
therapeutic strategies able to greatly reduce iron-related disorders.
Conﬂict of interest
The authors declare no conﬂict of interest.
Transparency documents
The Transparency documents associated with this article can be
found, in online version.
Acknowledgments
BS was ﬁnancially supported by FCT fellowship SFRH/BD/60718/
2009. This work was partially funded by Pest-OE/SAU/UI0009/2013.
References
[1] P.A. Frey, G.H. Reed, The ubiquity of iron, ACS Chem. Biol. 7 (2012) 1477–1481.
[2] N. Lane, W.F. Martin, The origin of membrane bioenergetics, Cell 151 (2012)
1406–1416.
[3] N.H. Sleep, A. Meibom, T. Fridriksson, R.G. Coleman, D.K. Bird, H2-rich ﬂuids from
serpentinization: geochemical and biotic implications, Proc. Natl. Acad. Sci. U. S.
A. 101 (2004) 12818–12823.
[4] D. Emerson, E.J. Fleming, J.M. McBeth, Iron-oxidizing bacteria: an environmental
and genomic perspective, Annu. Rev. Microbiol. 64 (2010) 561–583.
[5] O. Bretschger, A. Obraztsova, C.A. Sturm, I.S. Chang, Y.A. Gorby, S.B. Reed, D.E.
Culley, C.L. Reardon, S. Barua, M.F. Romine, J. Zhou, A.S. Beliaev, R. Bouhenni, D.
Saffarini, F. Mansfeld, B.H. Kim, J.K. Fredrickson, K.H. Nealson, Current production
and metal oxide reduction by Shewanella oneidensisMR-1 wild type and mutants,
Appl. Environ. Microbiol. 73 (2007) 7003–7012.
[6] B. Roche, L. Aussel, B. Ezraty, P. Mandin, B. Py, F. Barras, Iron/sulfur proteins biogen-
esis in prokaryotes: formation, regulation and diversity, Biochim. Biophys. Acta
1827 (2013) 455–469.
[7] I.C. Gunsalus, S.G. Sligar, T. Nordlund, H. Frauenfelder, Oxygen sensing heme
proteins: monoxygenases, myoglobin and hemoglobin, Adv. Exp. Med. Biol. 78
(1977) 37–50.
[8] M.F. White, M.S. Dillingham, Iron–sulphur clusters in nucleic acid processing
enzymes, Curr. Opin. Struct. Biol. 22 (2012) 94–100.
[9] D.D.Miller, L.A. Berner, Is solubility in vitro a reliable predictor of iron bioavailability?
Biol. Trace Elem. Res. 19 (1989) 11–24.
[10] B.C. Chu, A. Garcia-Herrero, T.H. Johanson, K.D. Krewulak, C.K. Lau, R.S. Peacock, Z.
Slavinskaya, H.J. Vogel, Siderophore uptake in bacteria and the battle for iron with
the host; a bird's eye view, Biometals 23 (2010) 601–611.
[11] C. Walling, R.E. Partch, T. Weil, Kinetics of the decomposition of hydrogen per-
oxide catalyzed by ferric ethylenediaminetetraacetate complex, Proc. Natl.
Acad. Sci. U. S. A. 72 (1975) 140–142.
1356 B. Silva, P. Faustino / Biochimica et Biophysica Acta 1852 (2015) 1347–1359[12] C.H. Park, B.R. Bacon, G.M. Brittenham, A.S. Tavill, Pathology of dietary carbonyl
iron overload in rats, Lab. Invest. 57 (1987) 555–563.
[13] R.W. Charlton, T.H. Bothwell, Iron absorption, Annu. Rev. Med. 34 (1983) 55–68.
[14] R.R. Crichton, M. Charloteaux-Wauters, Iron transport and storage, Eur. J. Biochem.
164 (1987) 485–506.
[15] K. Thorstensen, I. Romslo, The role of transferrin in the mechanism of cellular iron
uptake, Biochem. J. 271 (1990) 1–9.
[16] T. Ganz, Hepcidin—a regulator of intestinal iron absorption and iron recycling by
macrophages, Best Pract. Res. Clin. Haematol. 18 (2005) 171–182.
[17] P.A. Sharp, Intestinal iron absorption: regulation by dietary & systemic factors, Int.
J. Vitam. Nutr. Res. 80 (2010) 231–242.
[18] A.H. Laftah, G.O. Latunde-Dada, S. Fakih, R.C. Hider, R.J. Simpson, A.T. McKie, Haem
and folate transport by proton-coupled folate transporter/haem carrier protein 1
(SLC46A1), Br. J. Nutr. 101 (2009) 1150–1156.
[19] C.D. San Martin, C. Garri, F. Pizarro, T. Walter, E.C. Theil, M.T. Nunez, Caco-2 intes-
tinal epithelial cells absorb soybean ferritin by mu2 (AP2)-dependent endocytosis,
J. Nutr. 138 (2008) 659–666.
[20] A.T. McKie, D. Barrow, G.O. Latunde-Dada, A. Rolfs, G. Sager, E. Mudaly, M. Mudaly,
C. Richardson, D. Barlow, A. Bomford, T.J. Peters, K.B. Raja, S. Shirali, M.A. Hediger, F.
Farzaneh, R.J. Simpson, An iron-regulated ferric reductase associated with the ab-
sorption of dietary iron, Science 291 (2001) 1755–1759.
[21] R.S. Ohgami, D.R. Campagna, A. McDonald, M.D. Fleming, The Steap proteins are
metalloreductases, Blood 108 (2006) 1388–1394.
[22] H. Gunshin, B. Mackenzie, U.V. Berger, Y. Gunshin, M.F. Romero, W.F. Boron, S.
Nussberger, J.L. Gollan, M.A. Hediger, Cloning and characterization of a mammalian
proton-coupled metal-ion transporter, Nature 388 (1997) 482–488.
[23] B. Galy, D. Ferring-Appel, C. Becker, N. Gretz, H.J. Grone, K. Schumann, M.W.
Hentze, Iron regulatory proteins control a mucosal block to intestinal iron absorp-
tion, Cell Rep. 3 (2013) 844–857.
[24] N.T. Le, D.R. Richardson, Ferroportin1: a new iron export molecule? Int. J. Biochem.
Cell Biol. 34 (2002) 103–108.
[25] K.Y. Yeh, M. Yeh, L. Mims, J. Glass, Iron feeding induces ferroportin 1 and
hephaestin migration and interaction in rat duodenal epithelium, Am. J. Physiol.
Gastrointest. Liver Physiol. 296 (2009) G55–G65.
[26] G.M. Brittin, Q.T. Chee, Relation of ferroxidase (ceruloplasmin) to iron absorption, J.
Lab. Clin. Med. 74 (1969) 53–59.
[27] S. Young, A. Bomford, Transferrin and cellular iron exchange, Clin. Sci. (Lond.) 67
(1984) 273–278.
[28] P.J. Brown, P.M. Johnson, Isolation of a transferrin receptor structure from sodium
deoxycholate-solubilized human placental syncytiotrophoblast plasmamembrane,
Placenta 2 (1981) 1–10.
[29] M.D. Fleming, M.A. Romano, M.A. Su, L.M. Garrick, M.D. Garrick, N.C. Andrews,
Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for
Nramp2 in endosomal iron transport, Proc. Natl. Acad. Sci. U. S. A. 95 (1998)
1148–1153.
[30] C. Hershko, G. Graham, G.W. Bates, E.A. Rachmilewitz, Non-speciﬁc serum iron in
thalassaemia: an abnormal serum iron fraction of potential toxicity, Br. J. Haematol.
40 (1978) 255–263.
[31] M. Grootveld, J.D. Bell, B. Halliwell, O.I. Aruoma, A. Bomford, P.J. Sadler, Non-trans-
ferrin-bound iron in plasma or serum from patients with idiopathic hemochroma-
tosis. Characterization by high performance liquid chromatography and nuclear
magnetic resonance spectroscopy, J. Biol. Chem. 264 (1989) 4417–4422.
[32] J.P. Liuzzi, F. Aydemir, H. Nam, M.D. Knutson, R.J. Cousins, Zip14 (Slc39a14) medi-
ates non-transferrin-bound iron uptake into cells, Proc. Natl. Acad. Sci. U. S. A. 103
(2006) 13612–13617.
[33] P.A. Andrews, Disorders of iron metabolism, N. Engl. J. Med. 342 (2000) 1293
(author reply 1294).
[34] H. Shi, K.Z. Bencze, T.L. Stemmler, C.C. Philpott, A cytosolic iron chaperone that de-
livers iron to ferritin, Science 320 (2008) 1207–1210.
[35] A.D. Sheftel, A.S. Zhang, C. Brown, O.S. Shirihai, P. Ponka, Direct interorganellar
transfer of iron from endosome to mitochondrion, Blood 110 (2007) 125–132.
[36] G.C. Shaw, J.J. Cope, L. Li, K. Corson, C. Hersey, G.E. Ackermann, B. Gwynn, A.J.
Lambert, R.A. Wingert, D. Traver, N.S. Trede, B.A. Barut, Y. Zhou, E. Minet, A.
Donovan, A. Brownlie, R. Balzan, M.J. Weiss, L.L. Peters, J. Kaplan, L.I. Zon, B.H.
Paw, Mitoferrin is essential for erythroid iron assimilation, Nature 440 (2006)
96–100.
[37] X. Liu, E.C. Theil, Ferritin as an iron concentrator and chelator target, Ann. N. Y.
Acad. Sci. 1054 (2005) 136–140.
[38] S. Levi, B. Corsi, M. Bosisio, R. Invernizzi, A. Volz, D. Sanford, P. Arosio, J. Drysdale, A
human mitochondrial ferritin encoded by an intronless gene, J. Biol. Chem. 276
(2001) 24437–24440.
[39] J.A. Larson, H.L. Howie, M. So, Neisseria meningitidis accelerates ferritin degrada-
tion in host epithelial cells to yield an essential iron source, Mol. Microbiol. 53
(2004) 807–820.
[40] J. Mehlhase, G. Sandig, K. Pantopoulos, T. Grune, Oxidation-induced ferritin turn-
over in microglial cells: role of proteasome, Free Radic. Biol. Med. 38 (2005)
276–285.
[41] J.D. Mancias, X. Wang, S.P. Gygi, J.W. Harper, A.C. Kimmelman, Quantitative prote-
omics identiﬁes NCOA4 as the cargo receptormediating ferritinophagy, Nature 509
(2014) 105–109.
[42] R. Nilsson, I.J. Schultz, E.L. Pierce, K.A. Soltis, A. Naranuntarat, D.M. Ward, J.M.
Baughman, P.N. Paradkar, P.D. Kingsley, V.C. Culotta, J. Kaplan, J. Palis, B.H. Paw,
V.K. Mootha, Discovery of genes essential for heme biosynthesis through large-
scale gene expression analysis, Cell Metab. 10 (2009) 119–130.
[43] W.E. Dowdle, B. Nyfeler, J. Nagel, R.A. Elling, S. Liu, E. Triantafellow, S. Menon, Z.
Wang, A. Honda, G. Pardee, J. Cantwell, C. Luu, I. Cornella-Taracido, E. Harrington,P. Fekkes, H. Lei, Q. Fang, M.E. Digan, D. Burdick, A.F. Powers, S.B. Helliwell, S.
D'Aquin, J. Bastien, H. Wang, D. Wiederschain, J. Kuerth, P. Bergman, D. Schwalb,
J. Thomas, S. Ugwonali, F. Harbinski, J. Tallarico, C.J. Wilson, V.E. Myer, J.A. Porter,
D.E. Bussiere, P.M. Finan, M.A. Labow, X. Mao, L.G. Hamann, B.D. Manning, R.A.
Valdez, T. Nicholson, M. Schirle, M.S. Knapp, E.P. Keaney, L.O. Murphy, Selective
VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degra-
dation and iron homeostasis in vivo, Nat. Cell Biol. 16 (2014) 1069–1079.
[44] J.W. Pollard, Trophic macrophages in development and disease, Nat. Rev. Immunol.
9 (2009) 259–270.
[45] P.S. Low, S.M. Waugh, K. Zinke, D. Drenckhahn, The role of hemoglobin dena-
turation and band 3 clustering in red blood cell aging, Science 227 (1985)
531–533.
[46] A. Pantaleo, G. Giribaldi, F. Mannu, P. Arese, F. Turrini, Naturally occurring anti-
band 3 antibodies and red blood cell removal under physiological and pathological
conditions, Autoimmun. Rev. 7 (2008) 457–462.
[47] S.J. Lee, S.Y. Park, M.Y. Jung, S.M. Bae, I.S. Kim, Mechanism for phosphatidylserine-
dependent erythrophagocytosis in mouse liver, Blood 117 (2011) 5215–5223.
[48] G.J. Bosman, F.L. Willekens, J.M. Werre, Erythrocyte aging: a more than superﬁcial
resemblance to apoptosis? Cell. Physiol. Biochem. 16 (2005) 1–8.
[49] K.D. Poss, S. Tonegawa, Heme oxygenase 1 is required for mammalian iron reutili-
zation, Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 10919–10924.
[50] M. Kristiansen, J.H. Graversen, C. Jacobsen, O. Sonne, H.J. Hoffman, S.K. Law, S.K.
Moestrup, Identiﬁcation of the haemoglobin scavenger receptor, Nature 409
(2001) 198–201.
[51] S. Soe-Lin, S.S. Apte, B. Andriopoulos Jr., M.C. Andrews, M. Schranzhofer, T.
Kahawita, D. Garcia-Santos, P. Ponka, Nramp1 promotes efﬁcient macrophage
recycling of iron following erythrophagocytosis in vivo, Proc. Natl. Acad. Sci. U. S.
A. 106 (2009) 5960–5965.
[52] Z.L. Harris, A.P. Durley, T.K. Man, J.D. Gitlin, Targeted gene disruption reveals an es-
sential role for ceruloplasmin in cellular iron efﬂux, Proc. Natl. Acad. Sci. U. S. A. 96
(1999) 10812–10817.
[53] C. Finch, Regulators of iron balance in humans, Blood 84 (1994) 1697–1702.
[54] M.W. Gavin, D.M. McCarthy, P.J. Garry, Evidence that iron stores regulate iron
absorption—a setpoint theory, Am. J. Clin. Nutr. 59 (1994) 1376–1380.
[55] G. Nicolas, M. Bennoun, I. Devaux, C. Beaumont, B. Grandchamp, A. Kahn, S.
Vaulont, Lack of hepcidin gene expression and severe tissue iron overload in up-
stream stimulatory factor 2 (USF2) knockout mice, Proc. Natl. Acad. Sci. U. S. A.
98 (2001) 8780–8785.
[56] L. Lin, E.V. Valore, E. Nemeth, J.B. Goodnough, V. Gabayan, T. Ganz, Iron transferrin
regulates hepcidin synthesis in primary hepatocyte culture through hemojuvelin
and BMP2/4, Blood 110 (2007) 2182–2189.
[57] G. Nicolas, C. Chauvet, L. Viatte, J.L. Danan, X. Bigard, I. Devaux, C. Beaumont, A.
Kahn, S. Vaulont, The gene encoding the iron regulatory peptide hepcidin is regu-
lated by anemia, hypoxia, and inﬂammation, J. Clin. Invest. 110 (2002) 1037–1044.
[58] M. Vokurka, J. Krijt, K. Sulc, E. Necas, Hepcidin mRNA levels in mouse liver respond
to inhibition of erythropoiesis, Physiol. Res. 55 (2006) 667–674.
[59] H.N. Hunter, D.B. Fulton, T. Ganz, H.J. Vogel, The solution structure of human
hepcidin, a peptide hormone with antimicrobial activity that is involved in iron
uptake and hereditary hemochromatosis, J. Biol. Chem. 277 (2002) 37597–37603.
[60] E.V. Valore, T. Ganz, Posttranslational processing of hepcidin in human hepatocytes
is mediated by the prohormone convertase furin, Blood Cells Mol. Dis. 40 (2008)
132–138.
[61] E. Nemeth, M.S. Tuttle, J. Powelson, M.B. Vaughn, A. Donovan, D.M.Ward, T. Ganz, J.
Kaplan, Hepcidin regulates cellular iron efﬂux by binding to ferroportin and induc-
ing its internalization, Science 306 (2004) 2090–2093.
[62] B. Qiao, P. Sugianto, E. Fung, A. Del-Castillo-Rueda, M.J. Moran-Jimenez, T. Ganz, E.
Nemeth, Hepcidin-induced endocytosis of ferroportin is dependent on ferroportin
ubiquitination, Cell Metab. 15 (2012) 918–924.
[63] C.H. Park, E.V. Valore, A.J. Waring, T. Ganz, Hepcidin, a urinary antimicrobial
peptide synthesized in the liver, J. Biol. Chem. 276 (2001) 7806–7810.
[64] D.W. Swinkels, D. Girelli, C. Laarakkers, J. Kroot, N. Campostrini, E.H. Kemna, H.
Tjalsma, Advances in quantitative hepcidin measurements by time-of-ﬂight mass
spectrometry, PLoS One 3 (2008) e2706.
[65] H. Kulaksiz, E. Fein, P. Redecker, W. Stremmel, G. Adler, Y. Cetin, Pancreatic beta-
cells express hepcidin, an iron-uptake regulatory peptide, J. Endocrinol. 197
(2008) 241–249.
[66] H. Kulaksiz, F. Theilig, S. Bachmann, S.G. Gehrke, D. Rost, A. Janetzko, Y. Cetin, W.
Stremmel, The iron-regulatory peptide hormone hepcidin: expression and cellular
localization in the mammalian kidney, J. Endocrinol. 184 (2005) 361–370.
[67] S. Bekri, P. Gual, R. Anty, N. Luciani, M. Dahman, B. Ramesh, A. Iannelli, A. Staccini-
Myx, D. Casanova, I. Ben Amor, M.C. Saint-Paul, P.M. Huet, J.L. Sadoul, J. Gugenheim,
S.K. Srai, A. Tran, Y. Le Marchand-Brustel, Increased adipose tissue expression of
hepcidin in severe obesity is independent from diabetes and NASH, Gastroenterol-
ogy 131 (2006) 788–796.
[68] N.B. Nguyen, K.D. Callaghan, A.J. Ghio, D.J. Haile, F. Yang, Hepcidin expression and
iron transport in alveolar macrophages, Am. J. Physiol. Lung Cell. Mol. Physiol.
291 (2006) L417–L425.
[69] P.J. Schmidt, P.T. Toran, A.M. Giannetti, P.J. Bjorkman, N.C. Andrews, The transferrin
receptor modulates Hfe-dependent regulation of hepcidin expression, Cell Metab.
7 (2008) 205–214.
[70] E. Nemeth, S. Rivera, V. Gabayan, C. Keller, S. Taudorf, B.K. Pedersen, T. Ganz, IL-6
mediates hypoferremia of inﬂammation by inducing the synthesis of the iron reg-
ulatory hormone hepcidin, J. Clin. Invest. 113 (2004) 1271–1276.
[71] A.S. Zhang, J. Gao, D.D. Koeberl, C.A. Enns, The role of hepatocyte hemojuvelin in
the regulation of bone morphogenic protein-6 and hepcidin expression in vivo, J.
Biol. Chem. 285 (2010) 16416–16423.
1357B. Silva, P. Faustino / Biochimica et Biophysica Acta 1852 (2015) 1347–1359[72] Y. Xia, J.L. Babitt, Y. Sidis, R.T. Chung, H.Y. Lin, Hemojuvelin regulates hepcidin ex-
pression via a selective subset of BMP ligands and receptors independently of
neogenin, Blood 111 (2008) 5195–5204.
[73] J.L. Babitt, F.W. Huang, D.M. Wrighting, Y. Xia, Y. Sidis, T.A. Samad, J.A. Campagna,
R.T. Chung, A.L. Schneyer, C.J. Woolf, N.C. Andrews, H.Y. Lin, Bone morphogenetic
protein signaling by hemojuvelin regulates hepcidin expression, Nat. Genet. 38
(2006) 531–539.
[74] J. Truksa, H. Peng, P. Lee, E. Beutler, Bone morphogenetic proteins 2, 4, and 9 stim-
ulate murine hepcidin 1 expression independently of Hfe, transferrin receptor 2
(Tfr2), and IL-6, Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 10289–10293.
[75] J. Truksa, P. Lee, E. Beutler, Two BMP responsive elements, STAT, and bZIP/HNF4/
COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV re-
sponsiveness, Blood 113 (2009) 688–695.
[76] G. Casanovas, K. Mleczko-Sanecka, S. Altamura, M.W. Hentze, M.U. Muckenthaler,
Bone morphogenetic protein (BMP)-responsive elements located in the proximal
and distal hepcidin promoter are critical for its response to HJV/BMP/SMAD, J.
Mol. Med. (Berl.) 87 (2009) 471–480.
[77] D. Meynard, L. Kautz, V. Darnaud, F. Canonne-Hergaux, H. Coppin, M.P. Roth, Lack
of the bone morphogenetic protein BMP6 induces massive iron overload, Nat.
Genet. 41 (2009) 478–481.
[78] B. Andriopoulos Jr., E. Corradini, Y. Xia, S.A. Faasse, S. Chen, L. Grgurevic, M.D.
Knutson, A. Pietrangelo, S. Vukicevic, H.Y. Lin, J.L. Babitt, BMP6 is a key endogenous
regulator of hepcidin expression and iron metabolism, Nat. Genet. 41 (2009)
482–487.
[79] L. Kautz, D. Meynard, A. Monnier, V. Darnaud, R. Bouvet, R.H. Wang, C. Deng, S.
Vaulont, J. Mosser, H. Coppin, M.P. Roth, Iron regulates phosphorylation of
Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse
liver, Blood 112 (2008) 1503–1509.
[80] C.A. Enns, R. Ahmed, J. Wang, A. Ueno, C. Worthen, H. Tsukamoto, A.S. Zhang, In-
creased iron loading induces Bmp6 expression in the non-parenchymal cells of
the liver independent of the BMP-signaling pathway, PLoS One 8 (2013) e60534.
[81] L. Silvestri, A. Pagani, C. Camaschella, Furin-mediated release of soluble
hemojuvelin: a new link between hypoxia and iron homeostasis, Blood 111
(2008) 924–931.
[82] L. Lin, E. Nemeth, J.B. Goodnough, D.R. Thapa, V. Gabayan, T. Ganz, Soluble
hemojuvelin is released by proprotein convertase-mediated cleavage at a con-
served polybasic RNRR site, Blood Cells Mol. Dis. 40 (2008) 122–131.
[83] J.E. Maxson, C.A. Enns, A.S. Zhang, Processing of hemojuvelin requires retrograde
trafﬁcking to the Golgi in HepG2 cells, Blood 113 (2009) 1786–1793.
[84] A.J. Ramsay, J.D. Hooper, A.R. Folgueras, G. Velasco, C. Lopez-Otin, Matriptase-2
(TMPRSS6): a proteolytic regulator of iron homeostasis, Haematologica 94
(2009) 840–849.
[85] L. Silvestri, A. Pagani, A. Nai, I. De Domenico, J. Kaplan, C. Camaschella, The serine
protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving mem-
brane hemojuvelin, Cell Metab. 8 (2008) 502–511.
[86] A.S. Zhang, A.P. West Jr., A.E. Wyman, P.J. Bjorkman, C.A. Enns, Interaction of
hemojuvelin with neogenin results in iron accumulation in human embryonic kid-
ney 293 cells, J. Biol. Chem. 280 (2005) 33885–33894.
[87] A.S. Zhang, F. Yang, J. Wang, H. Tsukamoto, C.A. Enns, Hemojuvelin–neogenin in-
teraction is required for bone morphogenic protein-4-induced hepcidin expres-
sion, J. Biol. Chem. 284 (2009) 22580–22589.
[88] C.A. Enns, R. Ahmed, A.S. Zhang, Neogenin interacts with matriptase-2 to facilitate
hemojuvelin cleavage, J. Biol. Chem. 287 (2012) 35104–35117.
[89] C.N. Gross, A. Irrinki, J.N. Feder, C.A. Enns, Co-trafﬁcking of HFE, a nonclassical
major histocompatibility complex class I protein, with the transferrin receptor im-
plies a role in intracellular iron regulation, J. Biol. Chem. 273 (1998) 22068–22074.
[90] J. Gao, J. Chen, M. Kramer, H. Tsukamoto, A.S. Zhang, C.A. Enns, Interaction of the
hereditary hemochromatosis protein HFE with transferrin receptor 2 is required
for transferrin-induced hepcidin expression, Cell Metab. 9 (2009) 217–227.
[91] G. Ramey, J.C. Deschemin, S. Vaulont, Cross-talk between the mitogen activated
protein kinase and bone morphogenetic protein/hemojuvelin pathways is re-
quired for the induction of hepcidin by holotransferrin in primary mouse hepato-
cytes, Haematologica 94 (2009) 765–772.
[92] J. Gao, J. Chen, I. De Domenico, D.M. Koeller, C.O. Harding, R.E. Fleming, D.D.
Koeberl, C.A. Enns, Hepatocyte-targeted HFE and TFR2 control hepcidin expression
in mice, Blood 115 (2010) 3374–3381.
[93] F. D'Alessio, M.W. Hentze, M.U. Muckenthaler, The hemochromatosis proteins HFE,
TfR2, and HJV form a membrane-associated protein complex for hepcidin regula-
tion, J. Hepatol. 57 (2012) 1052–1060.
[94] G. Rishi, E.M. Crampton, D.F. Wallace, V.N. Subramaniam, In situ proximity ligation
assays indicate that hemochromatosis proteins Hfe and transferrin receptor 2
(Tfr2) do not interact, PLoS One 8 (2013) e77267.
[95] X.G. Wu, Y. Wang, Q. Wu, W.H. Cheng, W. Liu, Y. Zhao, C. Mayeur, P.J. Schmidt, P.B.
Yu, F. Wang, Y. Xia, HFE interacts with the BMP type I receptor ALK3 to regulate
hepcidin expression, Blood 124 (2014) 1335–1343.
[96] E. Nemeth, E.V. Valore, M. Territo, G. Schiller, A. Lichtenstein, T. Ganz, Hepcidin, a
putative mediator of anemia of inﬂammation, is a type II acute-phase protein,
Blood 101 (2003) 2461–2463.
[97] S. Rivera, E. Nemeth, V. Gabayan, M.A. Lopez, D. Farshidi, T. Ganz, Synthetic
hepcidin causes rapid dose-dependent hypoferremia and is concentrated in
ferroportin-containing organs, Blood 106 (2005) 2196–2199.
[98] P. Lee, H. Peng, T. Gelbart, L. Wang, E. Beutler, Regulation of hepcidin transcription
by interleukin-1 and interleukin-6, Proc. Natl. Acad. Sci. U. S. A. 102 (2005)
1906–1910.
[99] K. Inamura, Y. Matsuzaki, N. Uematsu, A. Honda, N. Tanaka, K. Uchida, Rapid inhi-
bition of MAPK signaling and anti-proliferation effect via JAK/STAT signaling byinterferon-alpha in hepatocellular carcinoma cell lines, Biochim. Biophys. Acta
1745 (2005) 401–410.
[100] D.M. Wrighting, N.C. Andrews, Interleukin-6 induces hepcidin expression through
STAT3, Blood 108 (2006) 3204–3209.
[101] V.H. Haase, Hypoxic regulation of erythropoiesis and iron metabolism, Am. J. Phys-
iol. Renal Physiol. 299 (2010) F1–F13.
[102] R.J. Kewley, M.L. Whitelaw, A. Chapman-Smith, The mammalian basic helix-loop-
helix/PAS family of transcriptional regulators, Int. J. Biochem. Cell Biol. 36 (2004)
189–204.
[103] P.H. Maxwell, M.S. Wiesener, G.W. Chang, S.C. Clifford, E.C. Vaux, M.E. Cockman,
C.C. Wykoff, C.W. Pugh, E.R. Maher, P.J. Ratcliffe, The tumour suppressor protein
VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis, Nature
399 (1999) 271–275.
[104] C.N. Lok, P. Ponka, Identiﬁcation of a hypoxia response element in the transferrin
receptor gene, J. Biol. Chem. 274 (1999) 24147–24152.
[105] C.K. Mukhopadhyay, B. Mazumder, P.L. Fox, Role of hypoxia-inducible factor-1 in
transcriptional activation of ceruloplasmin by iron deﬁciency, J. Biol. Chem. 275
(2000) 21048–21054.
[106] Y.M. Shah, T. Matsubara, S. Ito, S.H. Yim, F.J. Gonzalez, Intestinal hypoxia-inducible
transcription factors are essential for iron absorption following iron deﬁciency, Cell
Metab. 9 (2009) 152–164.
[107] P.J. Lee, B.H. Jiang, B.Y. Chin, N.V. Iyer, J. Alam, G.L. Semenza, A.M. Choi, Hypoxia-
inducible factor-1 mediates transcriptional activation of the heme oxygenase-1
gene in response to hypoxia, J. Biol. Chem. 272 (1997) 5375–5381.
[108] G.G. Braliou, M.V. Verga Falzacappa, G. Chachami, G. Casanovas, M.U.
Muckenthaler, G. Simos, 2-Oxoglutarate-dependent oxygenases control hepcidin
gene expression, J. Hepatol. 48 (2008) 801–810.
[109] S.O. Choi, Y.S. Cho, H.L. Kim, J.W. Park, ROS mediate the hypoxic repression of the
hepcidin gene by inhibiting C/EBPalpha and STAT-3, Biochem. Biophys. Res.
Commun. 356 (2007) 312–317.
[110] T. Sonnweber, D. Nachbaur, A. Schroll, M. Nairz, M. Seifert, E. Demetz, D.
Haschka, A.M. Mitterstiller, A. Kleinsasser, M. Burtscher, S. Trubsbach, A.T.
Murphy, V. Wroblewski, D.R. Witcher, K. Mleczko-Sanecka, C. Vecchi, M.U.
Muckenthaler, A. Pietrangelo, I. Theurl, G. Weiss, Hypoxia induced downregu-
lation of hepcidin is mediated by platelet derived growth factor BB, Gut 63
(2014) 1951–1959.
[111] L. Schito, S. Rey, M. Tafani, H. Zhang, C.C.Wong, A. Russo, M.A. Russo, G.L. Semenza,
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth fac-
tor B promotes lymphatic metastasis of hypoxic breast cancer cells, Proc. Natl.
Acad. Sci. U. S. A. 109 (2012) E2707–E2716.
[112] L.O. Jacobson, E. Goldwasser, W. Fried, L.F. Plzak, Studies on erythropoiesis. VII. The
role of the kidney in the production of erythropoietin, Trans. Assoc. Am. Phys. 70
(1957) 305–317.
[113] E.B. Rankin, M.P. Biju, Q. Liu, T.L. Unger, J. Rha, R.S. Johnson, M.C. Simon, B. Keith,
V.H. Haase, Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin
in vivo, J. Clin. Invest. 117 (2007) 1068–1077.
[114] D.R. Ashby, D.P. Gale, M. Busbridge, K.G. Murphy, N.D. Duncan, T.D. Cairns, D.H.
Taube, S.R. Bloom, F.W. Tam, R. Chapman, P.H. Maxwell, P. Choi, Erythropoietin ad-
ministration in humans causes a marked and prolonged reduction in circulating
hepcidin, Haematologica 95 (2010) 505–508.
[115] T. Tanno, N.V. Bhanu, P.A. Oneal, S.H. Goh, P. Staker, Y.T. Lee, J.W. Moroney, C.H.
Reed, N.L. Luban, R.H. Wang, T.E. Eling, R. Childs, T. Ganz, S.F. Leitman, S.
Fucharoen, J.L. Miller, High levels of GDF15 in thalassemia suppress expression of
the iron regulatory protein hepcidin, Nat. Med. 13 (2007) 1096–1101.
[116] T. Tanno, P. Porayette, O. Sripichai, S.J. Noh, C. Byrnes, A. Bhupatiraju, Y.T. Lee, J.B.
Goodnough, O. Harandi, T. Ganz, R.F. Paulson, J.L. Miller, Identiﬁcation of TWSG1
as a second novel erythroid regulator of hepcidin expression in murine and
human cells, Blood 114 (2009) 181–186.
[117] G. Casanovas, D.W. Swinkels, S. Altamura, K. Schwarz, C.M. Laarakkers, H.J. Gross,
M. Wiesneth, H. Heimpel, M.U. Muckenthaler, Growth differentiation factor 15 in
patients with congenital dyserythropoietic anaemia (CDA) type II, J. Mol. Med.
(Berl.) 89 (2011) 811–816.
[118] L. Kautz, G. Jung, E.V. Valore, S. Rivella, E. Nemeth, T. Ganz, Identiﬁcation of
erythroferrone as an erythroid regulator of iron metabolism, Nat. Genet. 46
(2014) 678–684.
[119] N. Patel, J. Varghese, P. Masaratana, G.O. Latunde-Dada, M. Jacob, R.J. Simpson, A.T.
McKie, The transcription factor ATOH8 is regulated by erythropoietic activity and
regulates HAMP transcription and cellular pSMAD1,5,8 levels, Br. J. Haematol.
164 (2014) 586–596.
[120] D.L. Zhang, R.M. Hughes, H. Ollivierre-Wilson, M.C. Ghosh, T.A. Rouault, A
ferroportin transcript that lacks an iron-responsive element enables duodenal
and erythroid precursor cells to evade translational repression, Cell Metab. 9
(2009) 461–473.
[121] H. Kawabata, R. Yang, T. Hirama, P.T. Vuong, S. Kawano, A.F. Gombart, H.P. Koefﬂer,
Molecular cloning of transferrin receptor 2. A new member of the transferrin
receptor-like family, J. Biol. Chem. 274 (1999) 20826–20832.
[122] N. Hubert, M.W. Hentze, Previously uncharacterized isoforms of divalent metal
transporter (DMT)-1: implications for regulation and cellular function, Proc. Natl.
Acad. Sci. U. S. A. 99 (2002) 12345–12350.
[123] A. Roetto, F. Di Cunto, R.M. Pellegrino, E. Hirsch, O. Azzolino, A. Bondi, I. Deﬁlippi, S.
Carturan, B. Miniscalco, F. Riondato, D. Cilloni, L. Silengo, F. Altruda, C. Camaschella,
G. Saglio, Comparison of 3 Tfr2-deﬁcient murinemodels suggests distinct functions
for Tfr2-alpha and Tfr2-beta isoforms in different tissues, Blood 115 (2010)
3382–3389.
[124] T. Glisovic, J.L. Bachorik, J. Yong, G. Dreyfuss, RNA-binding proteins and post-
transcriptional gene regulation, FEBS Lett. 582 (2008) 1977–1986.
1358 B. Silva, P. Faustino / Biochimica et Biophysica Acta 1852 (2015) 1347–1359[125] C.S. Lutz, A. Moreira, Alternative mRNA polyadenylation in eukaryotes: an effective
regulator of gene expression, Wiley Interdiscip. Rev. RNA 2 (2011) 23–31.
[126] B. Guo, F.M. Brown, J.D. Phillips, Y. Yu, E.A. Leibold, Characterization and expression
of iron regulatory protein 2 (IRP2). Presence of multiple IRP2 transcripts regulated
by intracellular iron levels, J. Biol. Chem. 270 (1995) 16529–16535.
[127] M. Sanchez, M. Bruguera, J. Rodes, R. Oliva, Complete characterization of the 3′ re-
gion of the human and mouse hereditary hemochromatosis HFE gene and detec-
tion of novel splicing forms, Blood Cells Mol. Dis. 27 (2001) 35–43.
[128] R. Martins, D. Proenca, B. Silva, C. Barbosa, A.L. Silva, P. Faustino, L. Romao, Alterna-
tive polyadenylation and nonsense-mediated decay coordinately regulate the
human HFE mRNA levels, PLoS One 7 (2012) e35461.
[129] T.W. Nilsen, B.R. Graveley, Expansion of the eukaryotic proteome by alternative
splicing, Nature 463 (2010) 457–463.
[130] R. Martins, B. Silva, D. Proenca, P. Faustino, Differential HFE gene expression
is regulated by alternative splicing in human tissues, PLoS One 6 (2011)
e17542.
[131] B. Silva, J. Ferreira, V. Santos, C. Baldaia, F. Serejo, P. Faustino, The soluble form of
HFE protein regulates hephaestin mRNA expression in the duodenum through
an endocytosis-dependent mechanism, Biochim. Biophys. Acta 1842 (2014)
2298–2305.
[132] M. Tabuchi, N. Tanaka, J. Nishida-Kitayama, H. Ohno, F. Kishi, Alternative splicing
regulates the subcellular localization of divalent metal transporter 1 isoforms,
Mol. Biol. Cell 13 (2002) 4371–4387.
[133] B.N. Patel, R.J. Dunn, S. David, Alternative RNA splicing generates a
glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammali-
an brain, J. Biol. Chem. 275 (2000) 4305–4310.
[134] C.P. Anderson, M. Shen, R.S. Eisenstein, E.A. Leibold, Mammalian iron metabolism
and its control by iron regulatory proteins, Biochim. Biophys. Acta 1823 (2012)
1468–1483.
[135] F. Samaniego, J. Chin, K. Iwai, T.A. Rouault, R.D. Klausner, Molecular characteriza-
tion of a second iron-responsive element binding protein, iron regulatory protein
2. Structure, function, and post-translational regulation, J. Biol. Chem. 269 (1994)
30904–30910.
[136] P.A. DeRusso, C.C. Philpott, K. Iwai, H.S. Mostowski, R.D. Klausner, T.A. Rouault,
Expression of a constitutive mutant of iron regulatory protein 1 abolishes iron
homeostasis in mammalian cells, J. Biol. Chem. 270 (1995) 15451–15454.
[137] D.C. Johnson, D.R. Dean, A.D. Smith, M.K. Johnson, Structure, function, and forma-
tion of biological iron–sulfur clusters, Annu. Rev. Biochem. 74 (2005) 247–281.
[138] M.L. Wallander, E.A. Leibold, R.S. Eisenstein, Molecular control of vertebrate iron
homeostasis by iron regulatory proteins, Biochim. Biophys. Acta 1763 (2006)
668–689.
[139] B. Guo, J.D. Phillips, Y. Yu, E.A. Leibold, Iron regulates the intracellular degradation
of iron regulatory protein 2 by the proteasome, J. Biol. Chem. 270 (1995)
21645–21651.
[140] A.A. Salahudeen, J.W. Thompson, J.C. Ruiz, H.W. Ma, L.N. Kinch, Q. Li, N.V. Grishin,
R.K. Bruick, An E3 ligase possessing an iron-responsive hemerythrin domain is a
regulator of iron homeostasis, Science 326 (2009) 722–726.
[141] T. Moroishi, M. Nishiyama, Y. Takeda, K. Iwai, K.I. Nakayama, The FBXL5-IRP2
axis is integral to control of iron metabolism in vivo, Cell Metab. 14 (2011)
339–351.
[142] M.C. Sammarco, S. Ditch, A. Banerjee, E. Grabczyk, Ferritin L and H subunits are dif-
ferentially regulated on a post-transcriptional level, J. Biol. Chem. 283 (2008)
4578–4587.
[143] A. Lymboussaki, E. Pignatti, G. Montosi, C. Garuti, D.J. Haile, A. Pietrangelo, The role
of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene ex-
pression, J. Hepatol. 39 (2003) 710–715.
[144] J.L. Casey, D.M. Koeller, V.C. Ramin, R.D. Klausner, J.B. Harford, Iron regulation of
transferrin receptor mRNA levels requires iron-responsive elements and a rapid
turnover determinant in the 3′ untranslated region of the mRNA, EMBO J. 8
(1989) 3693–3699.
[145] H. Gunshin, C.R. Allerson, M. Polycarpou-Schwarz, A. Rofts, J.T. Rogers, F. Kishi,
M.W. Hentze, T.A. Rouault, N.C. Andrews, M.A. Hediger, Iron-dependent regulation
of the divalent metal ion transporter, FEBS Lett. 509 (2001) 309–316.
[146] V. Ambros, microRNAs: tiny regulators with great potential, Cell 107 (2001)
823–826.
[147] L. He, G.J. Hannon, MicroRNAs: small RNAs with a big role in gene regulation, Nat.
Rev. Genet. 5 (2004) 522–531.
[148] M. Davis, S. Clarke, Inﬂuence of microRNA on the maintenance of human iron
metabolism, Nutrients 5 (2013) 2611–2628.
[149] K.B. Zumbrennen-Bullough, Q. Wu, A.B. Core, S. Canali, W. Chen, I. Theurl, D.
Meynard, J.L. Babitt, MicroRNA-130a is up-regulated in mouse liver by iron deﬁ-
ciency and targets the bonemorphogenetic protein (BMP) receptor ALK2 to atten-
uate BMP signaling and hepcidin transcription, J. Biol. Chem. 289 (2014)
23796–23808.
[150] H.P. Joshi, I.V. Subramanian, E.K. Schnettler, G. Ghosh, R. Rupaimoole, C. Evans, M.
Saluja, Y. Jing, I. Cristina, S. Roy, Y. Zeng, V.H. Shah, A.K. Sood, S. Ramakrishnan,
Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible
factors and ovarian cancer metastasis, Proc. Natl. Acad. Sci. U. S. A. 111 (2014)
5331–5336.
[151] R. Asci, F. Vallefuoco, I. Andolfo, M. Bruno, L. De Falco, A. Iolascon, Transferrin re-
ceptor 2 gene regulation by microRNA 221 in SH-SY5Y cells treated with
MPP(+) as Parkinson's disease cellular model, Neurosci. Res. 77 (2013) 121–127.
[152] S. Shpyleva, M. Pogribna, C. Cozart, M.S. Bryant, L. Muskhelishvili, V.P. Tryndyak,
S.A. Ross, F.A. Beland, I.P. Pogribny, Interstrain differences in the progression of
nonalcoholic steatohepatitis to ﬁbrosis in mice are associated with altered hepatic
iron metabolism, J. Nutr. Biochem. 25 (2014) 1235–1242.[153] S.H. Weitz, M. Gong, I. Barr, S. Weiss, F. Guo, Processing of microRNA primary tran-
scripts requires heme in mammalian cells, Proc. Natl. Acad. Sci. U. S. A. 111 (2014)
1861–1866.
[154] Y. Li, L. Lin, Z. Li, X. Ye, K. Xiong, B. Aryal, Z. Xu, Z. Paroo, Q. Liu, C. He, P. Jin, Iron
homeostasis regulates the activity of the microRNA pathway through poly(C)-
binding protein 2, Cell Metab. 15 (2012) 895–904.
[155] N.G. Seidah, A. Prat, The biology and therapeutic targeting of the proprotein
convertases, Nat. Rev. Drug Discov. 11 (2012) 367–383.
[156] J. Guillemot, M. Canuel, R. Essalmani, A. Prat, N.G. Seidah, Implication of the
proprotein convertases in iron homeostasis: proprotein convertase 7 sheds
human transferrin receptor 1 and furin activates hepcidin, Hepatology 57 (2013)
2514–2524.
[157] B. Gagliardo, N. Kubat, A. Faye, M. Jaouen, B. Durel, J.C. Deschemin, F. Canonne-
Hergaux, M.A. Sari, S. Vaulont, Pro-hepcidin is unable to degrade the iron exporter
ferroportin unless maturated by a furin-dependent process, J. Hepatol. 50 (2009)
394–401.
[158] N.C. Andrews, Disorders of iron metabolism, N. Engl. J. Med. 341 (1999)
1986–1995.
[159] Y. Deugnier, B. Turlin, Pathology of hepatic iron overload, World J. Gastroenterol.
13 (2007) 4755–4760.
[160] S.F. Clark, Iron deﬁciency anemia, Nutr. Clin. Pract. 23 (2008) 128–141.
[161] G. Weiss, L.T. Goodnough, Anemia of chronic disease, N. Engl. J. Med. 352 (2005)
1011–1023.
[162] E. Beutler, Iron storage disease: facts, ﬁction and progress, Blood Cells Mol. Dis. 39
(2007) 140–147.
[163] A. Pietrangelo, Hereditary hemochromatosis: pathogenesis, diagnosis, and treat-
ment, Gastroenterology 139 (2010) 393–408 (408 e391-392).
[164] J.N. Feder, A. Gnirke, W. Thomas, Z. Tsuchihashi, D.A. Ruddy, A. Basava, F.
Dormishian, R. Domingo Jr., M.C. Ellis, A. Fullan, L.M. Hinton, N.L. Jones, B.E.
Kimmel, G.S. Kronmal, P. Lauer, V.K. Lee, D.B. Loeb, F.A. Mapa, E. McClelland, N.C.
Meyer, G.A. Mintier, N. Moeller, T. Moore, E. Morikang, C.E. Prass, L. Quintana,
S.M. Starnes, R.C. Schatzman, K.J. Brunke, D.T. Drayna, N.J. Risch, B.R. Bacon, R.K.
Wolff, A novel MHC class I-like gene is mutated in patients with hereditary
haemochromatosis, Nat. Genet. 13 (1996) 399–408.
[165] A. Roetto, G. Papanikolaou, M. Politou, F. Alberti, D. Girelli, J. Christakis, D.
Loukopoulos, C. Camaschella, Mutant antimicrobial peptide hepcidin is associated
with severe juvenile hemochromatosis, Nat. Genet. 33 (2003) 21–22.
[166] G. Papanikolaou, M.E. Samuels, E.H. Ludwig, M.L. MacDonald, P.L. Franchini, M.P.
Dube, L. Andres, J. MacFarlane, N. Sakellaropoulos, M. Politou, E. Nemeth, J.
Thompson, J.K. Risler, C. Zaborowska, R. Babakaiff, C.C. Radomski, T.D. Pape, O.
Davidas, J. Christakis, P. Brissot, G. Lockitch, T. Ganz, M.R. Hayden, Y.P. Goldberg,
Mutations in HFE2 cause iron overload in chromosome 1q-linked juvenile hemo-
chromatosis, Nat. Genet. 36 (2004) 77–82.
[167] R.L. Sham, P.D. Phatak, C. West, P. Lee, C. Andrews, E. Beutler, Autosomal dominant
hereditary hemochromatosis associated with a novel ferroportin mutation and
unique clinical features, Blood Cells Mol. Dis. 34 (2005) 157–161.
[168] C. Camaschella, A. Roetto, A. Cali, M. De Gobbi, G. Garozzo, M. Carella, N. Majorano,
A. Totaro, P. Gasparini, The gene TFR2 is mutated in a new type of
haemochromatosis mapping to 7q22, Nat. Genet. 25 (2000) 14–15.
[169] P.C. Adams, D.M. Reboussin, J.C. Barton, C.E. McLaren, J.H. Eckfeldt, G.D. McLaren,
F.W. Dawkins, R.T. Acton, E.L. Harris, V.R. Gordeuk, C. Leiendecker-Foster, M.
Speechley, B.M. Snively, J.L. Holup, E. Thomson, P. Sholinsky, Hemochromatosis
and iron-overload screening in a racially diverse population, N. Engl. J. Med. 352
(2005) 1769–1778.
[170] A.T. Merryweather-Clarke, J.J. Pointon, J.D. Shearman, K.J. Robson, Global preva-
lence of putative haemochromatosis mutations, J. Med. Genet. 34 (1997) 275–278.
[171] J.N. Feder, Z. Tsuchihashi, A. Irrinki, V.K. Lee, F.A. Mapa, E. Morikang, C.E. Prass, S.M.
Starnes, R.K. Wolff, S. Parkkila, W.S. Sly, R.C. Schatzman, The hemochromatosis
founder mutation in HLA-H disrupts beta2-microglobulin interaction and cell sur-
face expression, J. Biol. Chem. 272 (1997) 14025–14028.
[172] M.W. Lawless, A.K. Mankan, M.White, M.J. O'Dwyer, S. Norris, Expression of hered-
itary hemochromatosis C282Y HFE protein in HEK293 cells activates speciﬁc endo-
plasmic reticulum stress responses, BMC Cell Biol. 8 (2007) 30.
[173] J.P. Pinto, P. Ramos, S.F. de Almeida, S. Oliveira, L. Breda, M. Michalak, G. Porto, S.
Rivella, M. de Sousa, Protective role of calreticulin in HFE hemochromatosis, Free
Radic. Biol. Med. 44 (2008) 99–108.
[174] A. Walsh, J.L. Dixon, G.A. Ramm, D.G. Hewett, D.J. Lincoln, G.J. Anderson, V.N.
Subramaniam, J. Dodemaide, J.A. Cavanaugh, M.L. Bassett, L.W. Powell, The clinical
relevance of compound heterozygosity for the C282Y and H63D substitutions in
hemochromatosis, Clin. Gastroenterol. Hepatol. 4 (2006) 1403–1410.
[175] J. Alvarez-Coca-Gonzalez, M.I. Moreno-Carralero, J. Martinez-Perez, M. Mendez, M.
Garcia-Ros, M.J. Moran-Jimenez, The hereditary hyperferritinemia–cataract syn-
drome: a family study, Eur. J. Pediatr. 169 (2010) 1553–1555.
[176] S. Kono, Aceruloplasminemia: an update, Int. Rev. Neurobiol. 110 (2013) 125–151.
[177] D. Aslan, K. Crain, E. Beutler, A new case of human atransferrinemia with a previ-
ously undescribed mutation in the transferrin gene, Acta Haematol. 118 (2007)
244–247.
[178] C. Beghe, A. Wilson, W.B. Ershler, Prevalence and outcomes of anemia in geriatrics:
a systematic review of the literature, Am. J. Med. 116 (Suppl. 7A) (2004) 3S–10S.
[179] J.D. Haas, T.T. Brownlie, Iron deﬁciency and reduced work capacity: a critical re-
view of the research to determine a causal relationship, J. Nutr. 131 (2001)
676S–688S (discussion 688S-690S).
[180] J.L. Beard, Iron biology in immune function, muscle metabolism and neuronal func-
tioning, J. Nutr. 131 (2001) 568S–579S (discussion 580S).
[181] K.R. Hartman, J.A. Barker, Microcytic anemia with iron malabsorption: an inherited
disorder of iron metabolism, Am. J. Hematol. 51 (1996) 269–275.
1359B. Silva, P. Faustino / Biochimica et Biophysica Acta 1852 (2015) 1347–1359[182] K.E. Finberg, M.M. Heeney, D.R. Campagna, Y. Aydinok, H.A. Pearson, K.R. Hartman,
M.M. Mayo, S.M. Samuel, J.J. Strouse, K. Markianos, N.C. Andrews, M.D. Fleming,
Mutations in TMPRSS6 cause iron-refractory iron deﬁciency anemia (IRIDA), Nat.
Genet. 40 (2008) 569–571.
[183] M. Castoldi, M. Vujic Spasic, S. Altamura, J. Elmen, M. Lindow, J. Kiss, J. Stolte, R.
Sparla, L.A. D'Alessandro, U. Klingmuller, R.E. Fleming, T. Longerich, H.J. Grone, V.
Benes, S. Kauppinen, M.W. Hentze, M.U. Muckenthaler, The liver-speciﬁc
microRNA miR-122 controls systemic iron homeostasis in mice, J. Clin. Invest.
121 (2011) 1386–1396.
[184] D.G. Schaar, D.J. Medina, D.F. Moore, R.K. Strair, Y. Ting, miR-320 targets transferrin
receptor 1 (CD71) and inhibits cell proliferation, Exp. Hematol. 37 (2009)
245–255.
[185] Y. Yoshioka, N. Kosaka, T. Ochiya, T. Kato, Micromanaging Iron Homeostasis:
hypoxia-inducible micro-RNA-210 suppresses iron homeostasis-related proteins,
J. Biol. Chem. 287 (2012) 34110–34119.
[186] Y. Liao, X. Du, B. Lonnerdal, miR-214 regulates lactoferrin expression and pro-
apoptotic function in mammary epithelial cells, J. Nutr. 140 (2010) 1552–1556.
[187] Y. Liao, B. Lonnerdal, miR-584 mediates post-transcriptional expression of
lactoferrin receptor in Caco-2 cells and inmouse small intestine during the perina-
tal period, Int. J. Biochem. Cell Biol. 42 (2010) 1363–1369.[188] I. Andolfo, L. De Falco, R. Asci, R. Russo, S. Colucci, M. Gorrese, M. Zollo, A.
Iolascon, Regulation of divalent metal transporter 1 (DMT1) non-IRE isoform
by the microRNA Let-7d in erythroid cells, Haematologica 95 (2010)
1244–1252.
[189] W. Hou, Q. Tian, N.M. Steuerwald, L.W. Schrum, H.L. Bonkovsky, The let-7
microRNA enhances heme oxygenase-1 by suppressing Bach1 and attenuates ox-
idant injury in human hepatocytes, Biochim. Biophys. Acta 1819 (2012)
1113–1122.
[190] W. Hou, Q. Tian, J. Zheng, H.L. Bonkovsky, MicroRNA-196 represses Bach1 protein
and hepatitis C virus gene expression in human hepatoma cells expressing hepati-
tis C viral proteins, Hepatology 51 (2010) 1494–1504.
[191] S.I. Shpyleva, V.P. Tryndyak, O. Kovalchuk, A. Starlard-Davenport, V.F. Chekhun, F.A.
Beland, I.P. Pogribny, Role of ferritin alterations in human breast cancer cells, Breast
Cancer Res. Treat. 126 (2011) 63–71.
[192] C. Sangokoya, J.F. Doss, J.T. Chi, Iron-responsive miR-485-3p regulates cellular iron
homeostasis by targeting ferroportin, PLoS Genet. 9 (2013) e1003408.
